

Wetenschappelijk overzicht IKNL 2024

Wetenschappelijk overzicht IKNL 2024

Auteur
A.M. Kuijpers-Ruurs

Geen inhoudsopgavegegevens gevonden. 1 Niet-tumorspecifiek

1.1 Publicaties met impactfactor

Adiprakoso D, [Katsimpokis D](#), [Oerlemans S](#), [Ezendam NP](#), [van Maaren MC](#), van Til JA, van der Heijden TG, [Mols F](#), [Aben KK](#), [Vink GR](#), Koopman M, [van de Poll-Franse LV](#), [de Rooij BH](#). Development of a prediction model for clinically-relevant fatigue: a multi-cancer approach. Qual Life Res. 2024 Nov 9. doi: 10.1007/s11136-024-03807-9. Online ahead of print.
Impactfactor: 3,3

Basten M, Pan KY, van Tuijl LA, de Graeff A, Dekker J, Hoogendoorn AW, Lamers F, Ranchor AV, Vermeulen R, Portengen L, [Voogd AC](#), Abell J, Awadalla P, Beekman AT, Bjerkeset O, Boyd A, Cui Y, Frank P, Galenkamp H, Garssen B, Hellingman S, Huisman M, Huss A, Keats MR, Kok AA, Krokstad S, van Leeuwen FE, Luik AI, Noisel N, Payette Y, Penninx BW, Rissanen I, Roest AM, Rosmalen JG, Ruiters R, Schoevers RA, Soave D, Spaan M, Steptoe A, Stronks K, Sund ER, Sweeney E, Twait EL, Teyhan A, Verschuren WM, van der Willik KD, Geerlings MI. Psychosocial factors, health behaviors and risk of cancer incidence: testing interaction and effect modification in an individual participant data meta-analysis. Int J Cancer. 2024 Jan 30. doi: 10.1002/ijc.34852. Online ahead of print.
Impactfactor: 5,7

[Boddaert MS](#), [Fransen HP](#), de Nijs EJ, van Gerven D, Spierings LE, [Raijmakers NJ](#), [van der Linden YM](#). Association between inappropriate end-of-life cancer care and specialist palliative care: a retrospective observational study in two acute care hospitals. Cancers (Basel). 2024 Feb 8;16(4):721. doi: 10.3390/cancers16040721.
Impactfactor: 4,5

Boomstra E, Walraven I, van der Ploeg IM, Wouters MW, van de Kamp MW, Dirven R, Albers E, Fraterman I, Poulissen M, [van de Poll-Franse LV](#), de Ligt KM. Moving beyond barriers: a mixed-method study to develop evidence-based strategies to improve implementation of PROMs in clinical oncology care. Qual Life Res. 2024 Sep 20. doi: 10.1007/s11136-024-03787-w. Online ahead of print.
Impactfactor: 3,3

Boomstra E, [Hommes S](#), Vromans RD, van der Burg S, Schrijver AM, Wouters MW, van der Ploeg IM, van de Kamp MW, Krahmer EJ, [van de Poll-Franse LV](#), de Ligt KM. "Numbers call for action, personalized narratives provide support and recognition": a qualitative assessment of cancer patients' perspectives on patient-reported outcome measures (PROMs) feedback with narratives. J Cancer Surviv. 2024 Sep 25. doi: 10.1007/s11764-024-01663-7. Online ahead of print.
Impactfactor: 3,1

Bootsma TI, van de Wal D, [Vlooswijk C](#), Roos DC, Drabbe C, Tissier R, Bijlsma RM, Kaal SE, Kerst JM, Tromp JM, Bos ME, van der Hulle T, Lalisang RI, Nuver J, Kouwenhoven MM, van der Graaf WT, Janssen SH, Husson O. Exploring the interconnectedness between health-related quality of life factors among long-term adolescent and young adult cancer survivors (AYAs): a network analysis. Support Care Cancer. 2024 Jan 13;32(2):104. doi: 10.1007/s00520-023-08295-0.
Impactfactor: 2,8

Brook TS, [Seetsen T](#), Dercksen MW, van Riel A, Derleyn VA, van den Bosch J, Nortier JW, Collett A, Georgopoulos NT, Bryk J, Breed WP, [van den Hurk CJ](#). Results of the Dutch scalp cooling registry in 7424 patients: analysis of determinants for scalp cooling efficacy. Oncologist. 2024 Jun 13;oyae116. doi: 10.1093/oncolo/oyae116. Online ahead of print.
Impactfactor: 4,8

Chan DC, Wong HC, Riad MA, Caini S, Wolf JR, [van den Hurk CJ](#), Beveridge M, Lam H, Bonomo P, Chow E, Behroozian T. Correction to: Prevention of radiation dermatitis with skin hygiene and washing: a systematic review and meta-analysis. Support Care Cancer. 2024 Jan 15;32(2):107. doi: 10.1007/s00520-024-08312-w.
Impactfactor: 2,8

Chan RJ, Knowles R, Ashbury FD, Bowen J, Chan A, Chin M, Olver I, Taylor C, Tinianov S, Alberti P, Bossi P, Brito-Dellan N, Cooksley T, Crawford GB, Dixit N, Fitch MI, Freedman JL, Ginex PK, Hart NH,

Hertz DL, Jefford M, Koczwara B, Naito T, Orsey AD, Ruhlmann CH, Tsoukalas N, **van den Hurk C**, van Seville Y, Wardill HR, Scotte F, Lustberg M; Multinational Association of Supportive Care in Cancer (MASCC) Study Group Chairs. Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care: an international Delphi study. *EClinicalMedicine*. 2024 Sep 11;76:102825. doi: 10.1016/j.eclinm.2024.102825. eCollection 2024 Oct. Impactfactor: 9,6

Dankers PW, Janssen SH, **van Eenbergen M**, Siflinger BM, van der Graaf WT, Husson O. Employment outcomes of adolescent and young adult (AYA) cancer survivors and their partners: a Dutch population-based study. *Cancer*. 2024 Feb 23. doi: 10.1002/cncr.35260. Online ahead of print. Impactfactor: 6,1

David C, Beijer S, Mols F, Oerlemans S, Husson O, Weijnenberg MP, **Ezendam NP**. Prevalence and determinants of sleep problems in cancer survivors compared to a normative population: a PROFILES registry study. *J Cancer Surviv*. 2024 Jul 24. doi: 10.1007/s11764-024-01641-z. Online ahead of print. Impactfactor: 3,1

de Heus E, Duijts SF, van der Zwan JM, van Herpen CML, **Merkx MA**, Rutherford MJ, Soerjomataram I. Measuring healthy life expectancy and determinants of poor perceived health: A population-based study among a subset of rare and common cancer survivors. *Cancer Epidemiol*. 2024 Nov 22;94:102706. doi: 10.1016/j.canep.2024.102706. Online ahead of print. Impactfactor: 2,4

de Vries S, Pijnappel L, Vervoort S, **van der Linden Y**, Teunissen S, de Graaf E. Attention to the values, wishes and needs of patients with advanced cancer by hospital clinicians: an exploratory qualitative study. *Am J Hosp Palliat Care*. 2024 Jun 18:10499091241261025. doi: 10.1177/10499091241261025. Online ahead of print. Impactfactor: 1,5

Delahousse J, Wagner AD, Borchmann S, Adjei AA, Haanen J, Burgers F, Letsch A, Quaas A, Oertelt-Prigione S, Oezdemir BC, **Verhoeven RH**, Della Pasqua O, Paci A, Mir O. Sex differences in the pharmacokinetics of anticancer drugs: a systematic review. *ESMO Open*. 2024 Dec 10;9(12):104002. doi: 10.1016/j.esmoop.2024.104002. Online ahead of print. Impactfactor: 7,1

Eng L, Chan RJ, Chan A, Charalambous A, Darling HS, Grech L, **van den Hurk CJ**, Kirk D, Mitchell SA, Poprawski D, Rammant E, Ramsey I, Fitch MI, Cheung YT. Perceived barriers toward patient-reported outcome implementation in cancer care: an international scoping survey. *JCO Oncol Pract*. 2024 Mar 8:OP2300715. doi: 10.1200/OP.23.00715. Online ahead of print. Impactfactor:4,7

Farrugia T, **Duijts SF**, Wilson C, Hemming L, Cockburn C, Spelten E. Addressing cancer survivors' information needs and satisfaction: a systematic review of potential intervention components for survivors with a rare cancer type. *Orphanet J Rare Dis*. 2024 Oct 18;19(1):387. doi: 10.1186/s13023-024-03403-7. Impactfactor: 3,4

Gavioli C, Vlooswijk C, Janssen SH, Kaal SE, Kerst JM, Tromp JM, Bos ME, van der Hulle T, van der Graaf WT, Lalisang RI, Nuver J, Bijlsma RM, Kouwenhoven MC, Husson O, **Beijer S**. Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations for cancer prevention in adolescent and young adult (AYA) cancer survivors: results from the SURVAYA study. *J Cancer Surviv*. 2024 Jan 15. doi: 10.1007/s11764-023-01529-4. Online ahead of print. Impactfactor: 3,1

Giusti F, Martos C, Carvalho RN, Zadnik V, **Visser O**, Bettio M, van Eycken L. Facing further challenges in cancer data quality and harmonisation. *Front Oncol*. 2024 Jul 25;14:1438805. doi: 10.3389/fonc.2024.1438805. eCollection 2024. Impactfactor: 3,5

Greidanus MA, van Ommen F, de Boer AG, Coenen P, **Duijts SF**. Experiences of unemployed and/or work-disabled cancer survivors who have pursued to return to paid employment: a focus group study. *J Cancer Surviv*. 2024 Aug 14. doi: 10.1007/s11764-024-01657-5. Online ahead of print.

Impactfactor: 3,1

Haaksman M, Ham L, Brom L, Baars A, van Basten JP, van den Borne BE, Hendriks MP, de Jong WK, van Laarhoven HW, van Lindert AS, Mandigers CM, van der Padt-Pruijsten A, Smilde TJ, van Zuylen LC, van Vliet LM, **Raijmakers NJ**. Open communication between patients and relatives about illness & death in advanced cancer-results of the eQuiPe Study. *Support Care Cancer*. 2024 Mar 6;32(4):214. doi: 10.1007/s00520-024-08379-5.

Impactfactor: 2,8

Ham L, Schelin ME, **Fransen HP**, Fürst CJ, van der Heide A, Korfage IJ, **Raijmakers NJ**, van Zuylen L, Hedman C. Death rituals and quality of life of bereaved relatives during the COVID-19 pandemic: results of the observational CO-LIVE study. *Death Stud*. 2024 Sep 11:1-10. doi: 10.1080/07481187.2024.2400354.

Online ahead of print.

Impactfactor: 2,1

Ham L, Fransen HP, de Graeff A, Hendriks MP, de Jong WK, Kloover J, Kuip E, Mandigers C, Sommeijer D, **van de Poll-Franse LV, Raijmakers NJ**, van Zuylen L. Relatives' unmet needs in the last year of life of patients with advanced cancer: results of a Dutch prospective, longitudinal study (eQuiPe). *J Palliat Care*. 2024 Mar 22:8258597241239614. doi: 10.1177/08258597241239614. Online ahead of print.

Impactfactor: 1,3

Heipon CS, Brom L, van der Linden YM, Tange D, Reyners AK, **Raijmakers NJ**. Characteristics of timely integration of palliative care into oncology hospital care for patients with incurable cancer: results of a Delphi Study. *Support Care Cancer*. 2024 May 3;32(5):324. doi: 10.1007/s00520-024-08508-0.

Impactfactor: 2,8

Hemming L, **Duijts SF**, Zomerdijk N, Cockburn C, Yuen E, Hardman R, Van Vuuren J, Farrugia T, Wilson C, Spelten E. A systematic review of peer support interventions to improve psychosocial functioning among cancer survivors: can findings be translated to survivors with a rare cancer living rurally? *Orphanet J Rare Dis*. 2024 Dec 20;19(1):473. doi: 10.1186/s13023-024-03477-3.

Impactfactor: 3,4

Hendriks MP, Jager A, **Ebben KC**, van Til JA, **Siesling S**. Clinical decision support systems for multidisciplinary team decision-making in patients with solid cancer: composition of an implementation model based on a scoping review. *Crit Rev Oncol Hematol*. 2024 Feb 2:104267. doi: 10.1016/j.critrevonc.2024.104267. Online ahead of print.

Impactfactor: 5,5

Hendriks RT, **van Eenbergen MC**, de Boer ML, Sleeman SH, Boll D, Husson O, Bootsma TI. 'There is still a part of me that would love to be the old me again', how do adolescents and young adults (AYA) experience cancer-related bodily changes: a phenomenological interview study. *J Cancer Surviv*. 2024 Apr 4. doi: 10.1007/s11764-024-01578-3. Online ahead of print.

Impactfactor: 3,1

Hinnen C, von Haeseler E, Tijssens F, **Mols F**. Adverse childhood events and mental health problems in cancer survivors: a systematic review. *Support Care Cancer*. 2024 Jan 4;32(1):80. doi: 10.1007/s00520-023-08280-7.

Impactfactor: 2,8

Hoffstädt HE, Verhoef MJ, Akkermans A, van der Steen JT, **Stoppelenburg A**, de Vries S, de Graaf E, Teunissen SC, **Hartog ID, van der Linden YM**. "Are you listening?": experiences shared online by family caregivers of patients in the palliative phase during the Covid-19-pandemic. *PLoS One*. 2024 Nov 14;19(11):e0310624. doi: 10.1371/journal.pone.0310624. eCollection 2024.

Impactfactor: 2,9

Hoffstädt HE, Tam MC, **Stoppelenburg A**, Stoevelaar R, van Bodegom-Vos L, van der Steen JT, **van der Linden YM, Hartog ID**. What do family caregivers of patients with life-threatening diseases need from healthcare professionals? a qualitative study. *BMJ Support Palliat Care*. 2024 Oct 2:spcare-2024-005135. doi: 10.1136/spcare-2024-005135. Online ahead of print.

Impactfactor: 2,0

Hosman FL, Rozemeijer SC, Zegers AD, Becker-Commissaris A, Klümpen HJ, van der Vorst MJ, **Brom L, Duijts SF**. Outcomes and feasibility of an occupational care programme (TERRA) to support work ability of rare and advanced cancer patients: a report of 7 cases. *Oncology*. 2024;102(5):350-358. doi: 10.1159/000534451. Epub 2023 Oct 12. Impactfactor: 2,5

Janssen SH, **Vlooswijk C**, Bijlsma RM, Kaal SE, Kerst JM, Tromp JM, Bos ME, van der Hulle T, Lalisang RI, Nuver J, Kouwenhoven MC, van der Graaf WT, Husson O. Health-related conditions among long-term cancer survivors diagnosed in adolescence and young adulthood (AYA): results of the SURVAYA study. *J Cancer Surviv*. 2024 May 13. doi: 10.1007/s11764-024-01597-0. Online ahead of print. Impactfactor: 3,1

Klaver KM, **Duijts SF**, Geusgens CA, Kieffer JM, van Rentergem JA, Hendriks MP, Nuver J, Marsman HA, Poppema BJ, Oostergo T, Doeksen A, Aarts MJ, Ponds RW, van der Beek AJ, Schagen SB. Internet-based cognitive rehabilitation for working cancer survivors: results of a multicenter randomized controlled trial. *JNCI Cancer Spectr*. 2024 Jan 25:pkad110. doi: 10.1093/jncics/pkad110. Online ahead of print. Impactfactor: 3,4

Klok JM, **Duijts SF**, Engelen V, Masselink R, Dingemans AC, Aerts JG, Lingsma HF, van Klaveren D. Experienced financial toxicity among long-term cancer survivors: results from a national cross-sectional survey. *J Cancer Surviv*. 2024 Sep 3. doi: 10.1007/s11764-024-01668-2. Online ahead of print. Impactfactor: 3,1

Kool M, Hafkamp E, Gol J, Aukema EJ, Malfitano C, Reyners A, Hales S, **van de Poll-Franse LV**, Rodin G, de Vries F. Managing cancer and living meaningfully (CALM): implementation in Dutch cancer care. *Psychooncology*. 2024 Jan;33(1):e6281. doi: 10.1002/pon.6281. Impactfactor: 3,3

Leducq S, Zaki F, **Hollestein LM**, Apfelbacher C, Ponna NP, Mazmudar R, Gran S. The majority of observational studies in leading peer-reviewed medicine journals are not registered and do not have a publicly accessible protocol: a scoping review. *J Clin Epidemiol*. 2024 Mar 29:111341. doi: 10.1016/j.jclinepi.2024.111341. Online ahead of print. Impactfactor: 7,3

Lehmann V, **Vlooswijk C**, van der Graaf WT, Bijlsma R, Kaal SE, Kerst JM, Tromp JM, Bos ME, van der Hulle T, Lalisang RI, Nuver J, Kouwenhoven MC, Lok CA, Beerendonk CC, Dinkelman-Smit M, Husson O. Pre-treatment fertility preservation and post-treatment reproduction in long-term survivors of adolescent and young adult (AYA) cancer. *J Cancer Surviv*. 2024 Feb 6. doi: 10.1007/s11764-024-01538-x. Online ahead of print. Impactfactor: 3,1

Luijken K, Lohmann A, Alter U, Claramunt Gonzalez J, **Clouth FJ**, Fossum JL, Heslen L, Huizing AH, Ketelaar J, Montoya AK, Nab L, Nijman RC, Penning de Vries BB, Tibbe TD, Wang YA, Groenwold RH. Replicability of simulation studies for the investigation of statistical methods: the RepliSims project. *R Soc Open Sci*. 2024 Jan 17;11(1):231003. doi: 10.1098/rsos.231003. eCollection 2024 Jan. Impactfactor: 2,9

Martos C, Giusti F, Van Eycken L, **Visser O**. Editorial: Joining efforts to improve data quality and harmonization among European population-based cancer registries. *Front Oncol*. 2024 Oct 9;14:1496574. doi: 10.3389/fonc.2024.1496574. eCollection 2024. Impactfactor: 3,5

Mercadé-Besora N, Guo Y, Du M, Li X, Ramírez-Anguita JM, Moreno A, Valente A, Villalobos F, Cheng IL, Carrasco-Ribelles LA, **van Swieten MM**, Merkelbach M, Magoya M, Lasalvia P, Pericàs Pulido P, Berg P, Bosco-Lévy P, Lillini R, Ribeiro R, Bagga TK, Ramella V, Khalid S, Mayer MA, Leis A, Jödicke AM, Burn E, Prieto-Alhambra D, Català M, Prats-Urbe A. Incident use of hydroxychloroquine for the treatment of rheumatoid arthritis and systemic lupus erythematosus during the COVID-19 pandemic. *Arthritis Care Res (Hoboken)*. 2024 Mar 25. doi: 10.1002/acr.25331. Online ahead of print. Impactfactor: 3,7

Michalek IM, Martos C, Caetano dos Santos FL, Giusti F, Degerlund H, Neamtii L, Taraszkiwicz L, van Eycken L, **Visser O**. Advancing data collection and analysis: 2023 revised European Network of Cancer Registries recommendations for standard dataset. *Eur J Cancer*. 2024 Jan 18;199:113557. doi: 10.1016/j.ejca.2024.113557. Online ahead of print. Impactfactor: 7,6

Mols F, Schoormans D, Oerlemans S, Horevoorts N, Ezendam NP, Raijmakers NJ, van de Poll-Franse LV. Patient-reported outcomes in cancer survivorship: insights from two decades of population-based PROFILES registry research. *J Cancer Surviv*. 2024 Oct 8. doi: 10.1007/s11764-024-01690-4. Online ahead of print. Impactfactor: 3,1

Padilla CS, **de Heus E**, Reuvers MJ, Schrieks M, Engelen V, Grunhagen D, Tesselaar ME, van der Graaf WT, **Duijts SF**, Husson O. Diagnostic trajectories of patients with rare cancer in the Netherlands: results from a nationwide cross-sectional survey. *Support Care Cancer*. 2024 Nov 19;32(12):807. doi: 10.1007/s00520-024-08998-y. Impactfactor: 2,8

Pan KY, van Tuijl L, Basten M, Rijnhart JJ, de Graeff A, Dekker J, Geerlings MI, Hoogendoorn A, Ranchor AV, Vermeulen R, Portengen L, **Voogd AC**, Abell J, Awadalla P, Beekman AT, Bjerkeset O, Boyd A, Cui Y, Frank P, Galenkamp H, Garssen B, Hellingman S, Hollander M, Huisman M, Huss A, Keats MR, Kok AA, Krokstad S, van Leeuwen FE, Luik AI, Noisel N, Payette Y, Penninx BW, Picavet S, Rissanen I, Roest AM, Rosmalen JG, Ruiters R, Schoevers RA, Soave D, Spaan M, Steptoe A, Stronks K, Sund ER, Sweeney E, Teyhan A, Twait EL, van der Willik KD, Lamers F. The mediating role of health behaviors in the association between depression, anxiety and cancer incidence: an individual participant data meta-analysis. *Psychol Med*. 2024 Apr 29;1-14. doi: 10.1017/S0033291724000850. Online ahead of print. Impactfactor: 5,9

Peirelinc H, Schulpen M, Hoogendijk R, Van Damme A, Pieters R, Henau K, van Damme N, **Karim-Kos HE**. Incidence, survival, and mortality of cancer in children and young adolescents in Belgium and the Netherlands in 2004-2015: a comparative population-based study. *Int J Cancer*. 2024 Mar 13. doi: 10.1002/ijc.34918. Online ahead of print. Impactfactor: 5,7

Pereira CF, Dijkhoorn AQ, Koekoek B, van den Broek M, van der Steen K, Engel M, van Rijn M, Meijers JM, Hasselaar J, van der Heide A, Onwuteaka-Philipsen BD, van den Beuken-van Everdingen MH, van der Linden YM, **Boddaert MS**, Jeurissen PP, **Merkx MA, Raijmakers NJ**. Potentially inappropriate end of life care and healthcare costs in the last 30 days of life in regions providing integrated palliative care in the Netherlands: a registration-based study. *Int J Integr Care*. 2024 Jul 8;24(3):6. doi: 10.5334/ijic.7504. eCollection 2024 Jul-Sep. Impactfactor: 2,6

Pham AT, **van Dijk BA**, van der Valk ES, van der Vegt B, van Rossum EF, de Bock GH. Chronic stress related to cancer incidence, including the role of metabolic syndrome components. *Cancers (Basel)*. 2024 May 28;16(11):2044. doi: 10.3390/cancers16112044. Impactfactor: 4,5

Rentiroia-Pacheco B, Bellomo D, Lakeman IM, Wakkee M, **Hollestein LM**, van Klaveren D. Weighted metrics are required when evaluating the performance of prediction models in nested case-control studies. *BMC Med Res Methodol*. 2024 May 17;24(1):115. doi: 10.1186/s12874-024-02213-6. Impactfactor: 3,9

Reuvers MJ, Burgers VW, **Vlooswijk C**, Verhees B, Husson O, van der Graaf WT. Same journey, different paths: caregiver burden among informal caregivers of adolescent and young adult patients with an Uncertain or Poor Cancer Prognosis (UPCP). *J Clin Med*. 2023 Dec 27;13(1):158. doi: 10.3390/jcm13010158. Impactfactor: 3,0

Shen L, **Visser E, van Erning FN, Geleijnse G**, Kaptein M. A two-step framework for validating causal effect estimates. *Pharmacoepidemiol Drug Saf*. 2024 Sep;33(9):e5873. doi: 10.1002/pds.5873. Impactfactor: 2,4

Signorelli C, Høeg BL, Asuzu C, Centeno I, Estapé T, Fisher P, Lam W, Levkovich I, Manne S, Miles A, Mullen L, Nekhlyudov L, Sade C, Shaw J, Singleton A, Travado L, Tsuchiya M, Lemmen J, Li J, Jefford M; International Psycho-Oncology Society Survivorship Special Interest Group (**Duijts SF**). International survey of psychosocial care for cancer survivors in low-/middle- and high-income countries: current practices, barriers, and facilitators to care. *JCO Glob Oncol*. 2024 May; 10:e2300418. doi: 10.1200/GO.23.00418.

Impactfactor: 43,2

Simons BC, Hillen MA, Aarts JW, Tromp JM, **de Heus E, Duijts SF**. Disentangling trust of patients with rare cancer in their healthcare professionals and the healthcare system: a qualitative interview study. *J Cancer Surviv*. 2024 Jan 16. doi: 10.1007/s11764-023-01531-w. Online ahead of print.

Impactfactor: 3,1

Slotman E, Weijzen F, **Fransen HP, van Hoeve JC**, Huijben AM, Kuip EJ, Jager A, **Kunst PW**, van Laarhoven HW, Tol J, Tjan-Heijnen VC, **Raijmakers NJ, van der Linden YM, Siesling S**; On-behalf-of-the-COVID-and-Cancer-NL Consortium. Continuity of care for patients with de novo metastatic cancer during the COVID-19 pandemic: a population-based observational study. *Int J Cancer*. 2024 Jan 24. doi: 10.1002/ijc.34857. Online ahead of print.

Impactfactor: 5,7

Trama A, Botta L, Stiller C, **Visser O**, Cañete-Nieto A, Spycher B, Bielska-Lasota M, Katalinic A, Vener C, Innos K, Marcos-Gragera R, Paapsi K, Guevara M, Demuru E, Mousavi SM, Blum M, Eberle A, Ferrari A, Bernasconi A, Lasalvia P; EUROCARE-6 Working Group. Survival of European adolescents and young adults diagnosed with cancer in 2010-2014. *Eur J Cancer*. 2024 Jan 24;202:113558. doi: 10.1016/j.ejca.2024.113558. Online ahead of print.

Impactfactor: 7,6

van der Heijden TG, de Ligt KM, Hubel NJ, van der Mierden S, Holzner B, **van de Poll-Franse LV, de Rooij BH**; EORTC Quality of Life Group. Exploring the role of health-related quality of life measures in predictive modelling for oncology: a systematic review. *Qual Life Res*. 2024 Dec 9. doi: 10.1007/s11136-024-03820-y. Online ahead of print.

Impactfactor: 3,3

van der Meer DJ, van der Graaf WT, van de Wal D, **Karim-Kos HE**, Husson O. Long-term second primary cancer risk in adolescent and young adult (15-39 years) cancer survivors: a population-based study in the Netherlands between 1989 and 2018. *ESMO Open*. 2024 Jan 2;9(1):102203. doi: 10.1016/j.esmoop.2023.102203. Online ahead of print.

Impactfactor: 7,1

van der Velden NC, Smets EM, van Vliet LM, **Brom L**, van Laarhoven HW, Henselmans I. Effects of prognostic communication strategies on emotions, coping, and appreciation of consultations: an experimental study in advanced cancer. *Palliat Support Care*. 2024 Mar 27:1-13. doi: 10.1017/S1478951524000403. Online ahead of print.

Impactfactor: 1,9

van der Velden NC, Smets EM, van Vliet LM, **Brom L**, van Laarhoven HW, Henselmans I. Effects of prognostic communication strategies on prognostic perceptions, treatment decisions and end-of-life anticipation in advanced cancer: an experimental study among analogue patients. *J Pain Symptom Manage*. 2024 Feb 28:S0885-3924(24)00647-X. doi: 10.1016/j.jpainsymman.2024.02.563. Online ahead of print.

Impactfactor: 3,2

van Ommen F, **Duijts SF**, Coenen P, Dalton SO, Kliffen A, van Hummel R, de Boer AG, Greidanus MA. Protocol of a randomized controlled trial on the effectiveness and cost-effectiveness of the PLACES intervention: a supported employment intervention aimed at enhancing work participation of unemployed and/or work-disabled cancer survivors. *Trials*. 2024 Sep 9;25(1):603. doi: 10.1186/s13063-024-08441-x. Impactfactor: 2,0

van Swieten MM, Haselgrove C. Editorial: Navigating the landscape of FAIR data sharing and reuse: repositories, standards, and resources. *Front Neuroinform.* 2024 Mar 1;18:1387758. doi: 10.3389/fninf.2024.1387758. eCollection 2024. Impactfactor: 2,5

van Teunenbroek KC, Mulder RL, Ahout IM, Bindels-de Heus KG, Delsman-van Gelder CM, Galimont-Collen AF, de Groot MA, Heitink-Polle KM, Looijestijn J, Mensink MO, Mulder S, Schieving JH, Schouten-van Meeteren AY, Verheijden JM, Rippen H, **Borggreve BC**, Kremer LC, Verhagen AA, Michiels EM; working groups symptom treatment and refractory symptom treatment of the Dutch paediatric palliative care guideline. A Dutch paediatric palliative care guideline: a systematic review and evidence-based recommendations for symptom treatment. *BMC Palliat Care.* 2024 Mar 13;23(1):72. doi: 10.1186/s12904-024-01367-w. Impactfactor: 2,5

Versluis MA, **van de Poll-Franse LV**, **Zijlstra M**, van Laarhoven HW, Vreugdenhil G, Henselmans I, **Brom L**, Kuip EJ, **van der Linden YM**, **Raijmakers NJ**. Changes in perception of prognosis in the last year of life of patients with advanced cancer and its associated factors: longitudinal results of the eQuiPe study. *Palliat Med.* 2024 Dec 4:2692163241301220. doi: 10.1177/02692163241301220. Online ahead of print. Impactfactor: 3,6

Vlooswijk C, Janssen SH, Sleeman SH, Pluis J, van der Graaf WT, **van de Poll-Franse LV**, Husson O, **van Eenbergen MC**. Identifying the informational needs and sources of support of Adolescent and Young Adult (AYA) cancer survivors to inform the development of a digital platform. *J Cancer Surviv.* 2024 Oct 18. doi: 10.1007/s11764-024-01679-z. Online ahead of print. Impactfactor: 3,1

Vos JA, Wollersheim BM, van Weert HC, **van de Poll-Franse LV**, van Asselt KM. General practitioners' experiences with implementing colon or prostate cancer survivorship care in primary care: a cross-sectional survey nested within two randomized-controlled trials. *JCO Oncol Pract.* 2024 Dec 2:OP2400491. doi: 10.1200/OP-24-00491. Online ahead of print. Impactfactor: 4,7

Wang Y, Allsop MJ, Epstein JB, Howell D, Rapoport BL, Schofield P, van Sebille Y, Thong MS, Walraven I, Ryan Wolf J, **van den Hurk CJ**. Patient-reported symptom monitoring: using (big) data to improve supportive care at the macro-, meso-, and micro-levels. *Support Care Cancer.* 2024 Feb 22;32(3):182. doi: 10.1007/s00520-024-08373-x. Impactfactor: 2,8

Western B, Ivarsson A, Vistad I, Demmelmaier I, Aaronson NK, Radcliffe G, van Beurden M, Bohus M, Courneya KS, Daley AJ, Galvão DA, Garrod R, Goedendorp MM, Griffith KA, van Harten WH, Hayes SC, Herrero-Roman F, Hiensch AE, Irwin ML, James E, Kenkhuis MF, Kersten MJ, Knoop H, Lucia A, May AM, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Oldenburg HS, Plotnikoff R, Schmidt ME, Schmitz KH, Schulz KH, Short CE, Sonke GS, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, **Velthuis MJ**, Wenzel J, Winters-Stone KM, Wiskemann J, Berntsen S, Buffart LM. Dropout from exercise trials among cancer survivors: an individual patient data meta-analysis from the POLARIS study. *Scand J Med Sci Sports.* 2024 Feb;34(2):e14575. doi: 10.1111/sms.14575. Impactfactor: 3,5

Wolkamp W, **Meijer J**, **van Hoeve JC**, **van Erning FN**, de Geus-Oei LF, **de Hingh I**, Veltman J, **Siesling S**; COVID and Cancer-NL Consortium. Impact of the COVID-19 pandemic on the in-hospital diagnostic pathway of breast and colorectal cancer in the Netherlands: a population-based study. *Cancer Med.* 2024 Jan 10. doi: 10.1002/cam4.6861. Online ahead of print. Impactfactor: 2,9

Wijlens KA, Witteveen A, Beenhakker L, **Siesling S**, Vollenbroek-Hutten MM, Bode C. Development process of a holistic assessment questionnaire to measure and monitor cancer-related fatigue. *Eur J Cancer Care.* 2024 Nov; 33(1). doi.org/10.1155/2024/2671255. Impactfactor: 1,8

1.2 Overige publicaties

Becker M, Veldhoven C, Kodde A, Lize N, **Beijer S**, **Raijmakers NJ**. Verborgen verdriet en boosheid door eetproblemen bij kanker. H&W 2024 Mrt. 67: p.15-18.

Ebben KC, van Vegchel T, Massa M, Sloep M, van der Werf J. Development and implementation of clinical decision algorithms for oncology. Stud Health Technol Inform. 2024 Aug 22;316:1348-1352. doi: 10.3233/SHTI240662.

Ebben KC, Vermeulen LR, Swinkels AC, Sloep M, van der Werf J. Development and implementation of semantic information standards for oncology. Stud Health Technol Inform. 2024 Aug 22;316:1358-1362. doi: 10.3233/SHTI240664.

Ebben KC, Swinkels AC, Dermois MM, van der Werf J, Vermeulen LR. Development and implementation of standardized, structured clinical reporting for oncology. Stud Health Technol Inform. 2024 Aug 22;316:1353-1357. doi: 10.3233/SHTI240663.

Hulsker CC, Schulp M, Mavinkurve-Groothuis AM, **Visser O**, Zsiros J, Wijnen MH, de Krijger RR, Bruggink AH, Looijeha LH, **Karim-Kos HE**, van der Steeg AF. Malignant extracranial germ cell tumors in the Netherlands between 1990 and 2018: stable incidence and improved survival. EJCped. 2024. doi.org/10.1016/j.ejcped.2024.100.148.

Massa M, Dermois MA, Caffarel J, Cramer-Van Der Welle CM, Boxman DKE, de Graaf E, Teunissen SS, **van der Werf J**. Towards a learning health system for symptom management in hospice care. Stud Health Technol Inform. 2024 Aug 22;316:66-67. doi: 10.3233/SHTI240347.

Swaminathan S, Salako O, Kundu D, Ddungu H, Enyi A, **van den Hurk CJ**, Allsop M, Ryan Wolf J. A perspective on inequities in the management of radiation dermatitis. Asia Pac J Oncol Nurs. 2024 Aug 31;11(10):100582. doi: 10.1016/j.apjon.2024.100582. eCollection 2024 Oct.

1.3 Proefschriften en promoties

de Heus HE. Rare versus common cancer in the Netherlands. Nijmegen: Radboud Universiteit; 29 februari 2024. Promotoren: **MA Merkx**, CM van Herpen. Copromotoren: **SF Duijts**, JM van der Zwan.

Dijxhoorn AF. Care about care for healthcare professionals providing palliative care. Leiden: LUMC; 22 mei 2024. Promotor: **YM van der Linden**.

Evers J. Radiotherapy treatment patterns in the Netherlands: insights from the Netherlands Cancer Registry. Enschede: Universiteit Twente; 25 april 2024. Promotor: **S Siesling**. Co-promotoren: **MJ Aarts**, MJ van der Sangen, H Struikmans.

Ham L. What about us?: experiences of relatives during end-of-life cancer care and bereavement. Tilburg: Tilburg University; 25 maart 2024. Promotoren: **LV van de Poll-Franse**, C van Zuylen. Copromotoren: **NJ Raijmakers**, **HP Fransen**.

Walraven JE. Towards sustainable multidisciplinary team meetings in oncology. Nijmegen: Radboud Universiteit; 24 mei 2024. Promotoren: JJ van der Hoeven, **VE Lemmens**. Copromotoren: IM Desar, **RH Verhoeven**.

2 Borstkanker

2.1 Publicaties met impactfactor

Ankersmid JW, Engelhardt EG, Lansink Rotgerink FK, The R, Strobbe LJ, Drossaert CH, **Siesling S**, van Uden-Kraan CF; Santeon VBHC Breast Cancer Group. Evaluation of the implementation of the Dutch breast cancer surveillance decision aid including personalized risk estimates in the SHOUT-BC study: a mixed methods approach. *Cancers (Basel)*. 2024 Mar 31;16(7):1390. doi: 10.3390/cancers16071390. Impactfactor: 4,5

Ankersmid JW, Drossaert CH, Strobbe LJ, Hackert MQ, Engels N, Prick JC, Teerenstra S, van Riet YE, The R, van Uden-Kraan CF, **Siesling S**; Santeon VBHC Breast Cancer Group. Shared decision-making supported by outcome information regarding surveillance after curative treatment for breast cancer: results of the SHOUT-BC study. *Eur J Cancer*. 2024 Nov 2;213:115107. doi: 10.1016/j.ejca.2024.115107. Online ahead of print. Impactfactor: 7,6

Bargon CA, Mink van der Molen DR, Young-Afat DA, Batenburg MC, van Dam IE, Baas IO, Ernst MF, Maarse W, Sier MF, Schoenmaeckers EJ, Burgmans JP, Bijlsma RM, **Siesling S**, Rakhorst HA, Mureau MA, van der Leij F, Doeksen A, Verkooijen HM; UMBRELLA Study Group. Clinical and patient-reported outcomes after oncoplastic versus conventional breast conserving surgery-a longitudinal, multicenter cohort study. *J Natl Cancer Inst*. 2024 Nov 29:djae310. doi: 10.1093/jnci/djae310. Online ahead of print. Impactfactor: 10,0

Cardoso MJ, de Boniface J, Dodwell D, Kaidar-Person O, Poortmans P, **van Maaren MC**. Which real indications remain for mastectomy? *Lancet Reg Health Am*. 2024 Apr 4;33:100734. doi: 10.1016/j.lana.2024.100734. eCollection 2024 May. Impactfactor: 7,0

Damman OC, van Strien-Knippenberg IS, Engelhardt EG, Determann D D, de Bruijne MC, **Siesling S**, Konings IR, Timmermans DR. Information and communication priorities of patients and healthcare professionals in shared decision making regarding adjuvant systemic breast cancer treatment: a survey study. *Eur J Oncol Nurs*. 2024 Apr 10;70:102574. doi: 10.1016/j.ejon.2024.102574. Online ahead of print. Impactfactor: 2,7

de Boo LW, Józwiak K, ter Hoeve ND, van Diest PJ, Opdam M, Wang Y, Schmidt MK, de Jong V, Kleiterp S, Cornelissen S, Baars D, Koornstra RH, Kerver ED, van Dalen T, Bins AD, Beeker A, van den Heiligenberg SM, de Jong PC, Bakker SD, Rietbroek RC, Konings IR, Blankenburgh R, Bijlsma RM, Imholz ALT, Stathonikos N, Vreuls W, Sanders J, Rosenberg EH, Koop EA, Varga Z, van Deurzen CH, Mooyaart AL, Córdoba A, Groen E, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, **Voogd AC**, van der Wall E, **Siesling S**, Salgado R, Dackus GM, Hauptmann M, Kok M, Linn SC. Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer. *ESMO Open*. 2024 Mar 6;9(3):102923. doi: 10.1016/j.esmoop.2024.102923. Online ahead of print. Impactfactor: 7,1

de Bruijn A, Schipper RJ, **Voogd AC**, Pullens MJ, Bloemen JG, **de Munck L**, van Riet YE, **Siesling S**, Vriens BE, Nieuwenhuijzen. Adding anti-HER2 therapy to neoadjuvant endocrine therapy seems effective in hormone receptor HER2 positive breast cancer patients unfit for chemotherapy: a nationwide population-based cohort study. *Cancers* 2024 Dec. 16(24), 4188. Impactfactor: 4,5

de Jonge C, Schipper RJ, Walstra CJ, Van Riet YE, Verrijssen AE, **Voogd AC**, van der Sangen MJ, Theuws J, Degreef E, Gielens MP, Bloemen JG, van den Berg HA, Nieuwenhuijzen GA. Breast conserving surgery with intraoperative electron beam radiation therapy for low-risk breast cancer: five-year follow-up of 306 patients. *Int J Cancer*. 2024 May 16. doi: 10.1002/ijc.35033. Online ahead of print. Impactfactor: 5,7

de Ligt KM, Koppert LB, **de Rooij BH**, **van de Poll-Franse LV**, Velikova G, Cardoso F. Seizing the moment: The time for harnessing electronic patient-reported outcome measures for enhanced and

sustainable metastatic breast cancer care is now. *Breast*. 2024 Feb 11;74:103676. doi: 10.1016/j.breast.2024.103676. Online ahead of print. Impactfactor: 5,7

de Wild SR, van Roozendaal LM, de Wilt JH, van Dalen T, van der Hage JA, van Duijnhoven FH, Simons JM, Schipper RJ, **de Munck L**, van Kuijk SM, Boersma LJ, Linn SC, Lobbes MB, Poortmans PM, Tjan-Heijnen VC, van de Vijver KK, de Vries J, Westenberg AH, Strobbe LJ, Smidt ML. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07). *Br J Surg*. 2024 Apr 3;111(4):znae077. doi: 10.1093/bjs/znae077. Impactfactor: 8,7

Evers J, van der Sangen MJ, **van Maaren MC**, Maduro JH, Strobbe L, Aarts MJ, Bloemers MC, Wesseling J, van den Bongard DH, Struikmans H, **Siesling S**. Deintensification of radiotherapy use in treatment of ductal carcinoma in situ in the Netherlands: a nationwide overview from 2008 until 2022. *Clin Oncol (R Coll Radiol)*. 2024 Dec 17;38:103740. doi: 10.1016/j.clon.2024.103740. Online ahead of print. Impactfactor: 3,2

Evers J, van der Sangen MJ, **van Maaren MC**, Maduro JH, Strobbe L, **Aarts MJ**, Bloemers MC, van den Bongard DH, Struikmans H, **Siesling S**. Radiotherapy trends and variations in invasive non-metastatic breast cancer treatment in the Netherlands: a nationwide overview from 2008 to 2019. *Clin Oncol (R Coll Radiol)*. 2024 Aug 22;S0936-6555(24)00367-4. doi: 10.1016/j.clon.2024.08.010. Online ahead of print. Impactfactor: 3,2

Eijkelboom AH, Stam MR, van den Bongard DH, Sattler MG, Bantema-Joppe EJ, **Siesling S**, **van Maaren MC**. Implementation of ultra-hypofractionated radiotherapy schedules for breast cancer during the COVID-19 pandemic in the Netherlands. *Clin Transl Radiat Oncol*. 2024 Jun 14;47:100807. doi: 10.1016/j.ctro.2024.100807. eCollection 2024 Jul. Impactfactor: 2,7

Geurts VCM, Balduzzi S, Steenbruggen TG, Linn SC, **Siesling S**, Badve SS, DeMichele A, Ignatiadis M, Leon-Ferre RA, Goetz MP, Wolff AC, Klar N, Michiels S, Loi S, Adams S, Horlings HM, Sonke GS, Salgado R, Kok M. Tumor-infiltrating lymphocytes in patients with stage I triple-negative breast cancer untreated with chemotherapy. *JAMA Oncol*. 2024 Jun 27. doi: 10.1001/jamaoncol.2024.1917. Online ahead of print. Impactfactor: 22,3

Huberts AS, Albers EA, de Ligt KM, Koppert LB, Schagen SB, **van de Poil-Franse LV**. Self-perceived cognitive impairment in the first year after breast cancer and the identification of at-risk patients. *Eur J Oncol Nurs*. 2024 Oct;72:102685. doi: 10.1016/j.ejon.2024.102685. Epub 2024 Aug 20. Impactfactor: 2,7

Kaidar-Person O, Sklair-Levy M, Anaby D, Bernstein-Molho R, **van Maaren MC**, **de Munck L**, de Ruyscher D, Offersen B, Poortmans P, Boersma LJ; SECRET group. Residual breast tissue after mastectomy and reconstruction: a substudy of the Spatial location of breast cancer local rECurRence aftEr masTectomy (SECRET) project. *Eur J Surg Oncol*. 2024 Aug 16;50(11):108607. doi: 10.1016/j.ejso.2024.108607. Online ahead of print. Impactfactor: 3,5

Lammers SW, Geurts SM, Hermans KE, van Hellemond IE, **Swinkels AC**, Smorenburg CH, van der Sangen MJ, Kroep JR, Honkoop AH, van den Berkmoortel FW, de Roos WK, Imholz AL, Vriens IJ, Tjan-Heijnen VC; Dutch Breast Cancer Research Group (BOOG) for the DATA investigators. Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial. *Breast Cancer Res Treat*. 2024 Jun 28. doi: 10.1007/s10549-024-07411-w. Online ahead of print. Impactfactor: 3,0

Lammers SW, Meegdes M, Vriens IJ, **Voogd AC**, **de Munck L**, van Nijnatten TJ, Keymeulen KB, Tjan-Heijnen VC, Geurts SM. Treatment and survival of patients diagnosed with high-risk HR+/HER2- breast cancer in the Netherlands: a population-based retrospective cohort study. *ESMO Open*. 2024 Apr 26;9(5):103008. doi: 10.1016/j.esmooop.2024.103008. Online ahead of print.

Impactfactor: 7,1

Lemij A, de Glas N, Kroep J, **Siesling S**, van den Bos F, Bastiaannet E, Liefers GJ, Portielje J. A comparison of treatment allocation and survival between younger and older patients with HER2-overexpressing de novo metastatic breast cancer. *J Geriatr Oncol*. 2024 Jun 7;15(6):101805. doi: 10.1016/j.jgo.2024.101805. Online ahead of print.

Impactfactor: 3,0

Liefaard MC, van der Voort A, van Seijen M, Thijssen B, Sanders J, Vonk S, Mittempergher L, Bhaskaran R, **de Munck L**, van Leeuwen-Stok AE, Salgado R, Horlings HM, Lips EH, Sonke GS. Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade. *NPJ Breast Cancer*. 2024 Apr 18;10(1):29. doi: 10.1038/s41523-024-00636-4.

Impactfactor: 6,6

Meurs CJ, Kerkhoven C, **Siesling S**, Menke-Pluijmers MB, Westenend PJ. Surgery for classic, pleomorphic and non-classic lobular carcinoma in situ: surgery rate, risk of upstaging and short-term follow-up. *Ann Surg Oncol*. 2024 Dec 30. doi: 10.1245/s10434-024-16686-8. Online ahead of print.

Impactfactor: 3,4

Morgan E, O'Neill C, Bardot A, Walsh P, Woods RR, Gonsalves L, Hawkins S, Nygård JF, Negoita S, **Ramirez-Pena E**, Gelmon K, **Siesling S**, Cardoso F, Gralow J, Soerjomataram I, Arnold M. Collecting long-term outcomes in population-based cancer registry data: the case of breast cancer recurrence. *JCO Glob Oncol*. 2024 Oct;10:e2400249. doi: 10.1200/GO-24-00249. Epub 2024 Oct 31.

Impactfactor: 3,2

Morgan E, O'Neill C, Shah R, Langselius O, Su Y, Frick C, Fink H, Bardot A, Walsh PM, Woods RR, Gonsalves L, Nygård JF, Negoita S, Ramirez-Pena E, Gelmon K, Antone N, Mutebi M, **Siesling S**, Cardoso F, Gralow J, Soerjomataram I, Arnold M. Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis. *Breast Cancer Res*. 2024 Nov 27;26(1):171. doi: 10.1186/s13058-024-01881-y.

Impactfactor: 6,1

Naaktgeboren WR, Koevoets EW, Stuiver MM, van Harten WH, Aaronson NK, van der Wall E, **Velthuis M**, Sonke G, Schagen SB, Groen WG, May AM. Effects of physical exercise during adjuvant chemotherapy for breast cancer on long-term tested and perceived cognition: results of a pragmatic follow-up study. *Breast Cancer Res Treat*. 2024 Jan 29. doi: 10.1007/s10549-023-07220-7. Online ahead of print.

Impactfactor: 3,0

O'Leary RL, Duijm LE, Boersma LJ, van der Sangen MJ, **de Munck L**, Wesseling J, Schipper RJ, **Voogd AC**. Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade. *Br J Cancer*. 2024 Jul 9. doi: 10.1038/s41416-024-02785-6. Online ahead of print.

Impactfactor: 6,4

Peeters NJ, **Vlooswijk C**, Bijlsma RM, Kaal SE, Kerst JM, Tromp JM, Bos ME, van der Hulle T, Lalisang RI, Nuver J, Kouwenhoven MC, van der Ploeg IM, van der Graaf WT, Husson O. Sexual quality of life of adolescents and young adult breast cancer survivors. *ESMO Open*. 2024 Jan 27;9(2):102234. doi: 10.1016/j.esmoop.2024.102234. Online ahead of print.

Impactfactor: 7,1

Ploumen RA, Claassens EL, Kooreman LF, Keymeulen KB, van Kats MA, van Kuijk SM, **Siesling S**, van Nijnatten TJ, Smidt ML. Surgical outcomes and prognosis of HER2+ invasive breast cancer patients with a DCIS component treated with breast-conserving surgery after neoadjuvant systemic therapy. *Eur J Surg Oncol*. 2024 Jun 4;50(9):108465. doi: 10.1016/j.ejso.2024.108465. Online ahead of print.

Impactfactor: 3,5

Ploumen RA, van Nijnatten TJ, Kooreman LF, **Voogd AC**, Keymeulen KB, **Siesling S**, Smidt ML. Surgical treatment after neoadjuvant systemic therapy for HER2-positive invasive breast cancer in the Netherlands: 10-Year trends and the influence an accompanying DCIS component. *Breast*. 2024 Nov 26;79:103854. doi: 10.1016/j.breast.2024.103854. Online ahead of print.

Impactfactor: 5,7

Rajan KK, Nijveldt JJ, Verheijen S, **Siesling S**, Beek MA, Francken AB. Adherence to guideline recommendations for follow-up in patients with DCIS at a large teaching hospital in the Netherlands. *Breast Cancer Res Treat.* 2024 Jun 14. doi: 10.1007/s10549-024-07391-x. Online ahead of print. Impactfactor: 3,0

Schipper RJ, de Bruijn A, van der Sangen MJ, Bloemen JG, van den Hoven I, Schepers EE, Vriens BE, Boerman T, Rijkaart DC, van de Winkel LM, Brouwer C, van Warmerdam LJ, Gielens MP, van Bommel RM, van Riet YE, **Voogd AC**, Nieuwenhuijzen GA. Oncologic outcomes of de-escalating axillary treatment in clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy: a two center cohort study. *Eur J Surg Oncol.* 2024 Jun 5;50(9):108472. doi: 10.1016/j.ejso.2024.108472. Online ahead of print. Impactfactor: 3,5

Schreurs MA, Schmidt MK, Hollestelle A, Schaapveld M; Hereditary Breast and Ovarian Cancer Research Group Netherlands (**Siesling S, Verloop J**); van Asperen CJ, Ausems MG, van de Beek I, Broekema MF, Collée JM, van der Hout AH, van Kaam KJ, Komdeur FL, Mensenkamp AR, Adank MA, Hooning M. Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families. *Genet Med.* 2024 May 31:101171. doi: 10.1016/j.gim.2024.101171. Online ahead of print. Impactfactor: 6,7

Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, **Swinkels AC**, Blommestein HM, Guerrero Paez C, **Mol L**, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van Schaik-van de Mheen C, Tol J, Tromp-van Driel CS, Vrijaldenhoven S, van Leeuwen-Stok AE, Konings IR, Jager A; SONIA Study Consortium. Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer. *Nature.* 2024 Nov 27. doi: 10.1038/s41586-024-08035-2. Online ahead of print. Impactfactor: 50,5

ten Velde DE, Duijm LE, van der Sangen MJ, Schipper RJ, Tjan-Heijnen VC, Vreuls W, Strobbe LJ, **Voogd AC**. Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme. *Br J Cancer.* 2024 Mar 11. doi: 10.1038/s41416-024-02633-7. Online ahead of print. Impactfactor: 6,4

van Maaren MC, van Hove JC, Korevaar JC, van Hezewijk M, Siemerink EJ, Zeillemaker AM, **Klaassen-Dekker A**, van Uden DJ, Volders JH, Drossaert CC, **Siesling S**; NABOR project group. The effectiveness of personalised surveillance and aftercare in breast cancer follow-up: a systematic review. *Support Care Cancer.* 2024 May 2;32(5):323. doi: 10.1007/s00520-024-08530-2. Impactfactor: 2,8

van Maaren MC, Hueting TA, van Uden DJ, van Hezewijk M, **de Munck L**, Mureau MA, Seegers PA, Voorham QJ, Schmidt MK, Sonke GS, Groothuis-Oudshoorn CG, **Siesling S**; NABOR project group. The INFLUENCE 3.0 model: updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy. *Breast.* 2024 Oct 28;79:103829. doi: 10.1016/j.breast.2024.103829. Online ahead of print. Impactfactor: 5,7

Verhoeven D, **Siesling S**, Allemani C, Roy PG, Travado L, Bhoo-Pathy N, Rhayns C, Junkermann H, Nakamura S, Lasebikan N, Tucker FL. High-value breast cancer care within resource limitations. *Oncologist.* 2024 May 23;oyae080. doi: 10.1093/oncolo/oyae080. Online ahead of print. Impactfactor: 4,8

Verreck EE, Kuijjer A, van Steenhoven JE, Volders JH, van der Velden AW, **Siesling S**, Timmer-Bonte AN, Smilde TJ, Imholz AL, Blanken-Peeters CF, de Valk B, Vrijaldenhoven S, Lastdrager WB, Haringhuizen AW, Hunting JC, Hovenga S, Nieboer P, Zuetenhorst HM, Tetteroo GW, Smorenburg CH, **van Maaren MC**, van Dalen T. 70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study. *Breast Cancer Res Treat.* 2024 Sep 30. doi: 10.1007/s10549-024-07496-3. Online ahead of print. Impactfactor: 3,0

Voets MM, Hassink NS, Veltman J, Slump CH, Koffijberg H, **Siesling S**. Opportunities for personalised follow-up in breast cancer: the gap between daily practice and recurrence risk. *Breast Cancer Res Treat*. 2024 Feb 26. doi: 10.1007/s10549-024-07246-5. Online ahead of print. Impactfactor: 3,0

Vrancken Peeters NJ, van Til JA, Huberts AS, **Siesling S**, Husson O, Koppert LB. Internal responsiveness of EQ-5D-5L and EORTC QLQ-C30 in Dutch breast cancer patients during the first year post-surgery: a longitudinal cohort study. *Cancers* 2024, 16(11), 1952; <https://doi.org/10.3390/cancers16111952>. Impactfactor: 4,5

Vrancken-Peeters NJ, Koppert LB, Jager A, **Hendriks MP, Siesling S, van den Hurk CJ**. Symptom monitoring and health-related quality of life in non-metastatic breast cancer patients: a systematic review. *Curr Breast Cancer Rep*. 2024 Jul;16:417-428. Impactfactor: 1,0

Wang Y, Dackus GM, Rosenberg EH, Cornelissen S, de Boo LW, Broeks A, Brugman W, Chan TW, van Diest PJ, Hauptmann M, ter Hoeve ND, Isaeva OI, de Jong VM, Józwiak K, Kluin RJ, Kok M, Koop E, Nederlof PM, Opdam M, Schouten PC, **Siesling S**, van Steenis C, Voogd AC, Vreuls W, Salgado RF, Linn SC, Schmidt MK. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status. *BMC Med*. 2024 Jan 9;22(1):9. doi: 10.1186/s12916-023-03233-7. Impactfactor: 7,1

Westenend P, Meurs C, van Bekkum S, van Rosmalen J, Menke-Pluijmers M, **Siesling S**. ASO Author reflections: what can prediction models for upstaging of DCIS diagnosed on biopsy tell us about DCIS surveillance trials? *Ann Surg Oncol*. 2024 Jan 25. doi: 10.1245/s10434-024-14964-z. Online ahead of print. Impactfactor: 3,4

Wong HC, Lee SF, Caini S, Chan AW, Kwan JY, Waddle M, Sonis S, Herst P, Alcorn S, Bonomo P, Wong C, Corbin K, Choi JI, Rembielak A, AlKhaifi M, Marta GN, Rades D, **van den Hurk C**, Wolf JR, Chan RJ, Schmeel LC, Lock M, Hijal T, Cao J, Kim H, Chow E. Barrier films or dressings for the prevention of acute radiation dermatitis in breast cancer: a systematic review and network meta-analysis. *Breast Cancer Res Treat*. 2024 Aug 7. doi: 10.1007/s10549-024-07435-2. Online ahead of print. Impactfactor: 3,0

Wong HC, Wallen MP, Chan AW, Dick N, Bonomo P, Bareham M, Wolf JR, **van den Hurk C**, Fitch M, Chow E, Chan RJ; MASCC BCRAL Expert Panel and the Oncodermatology and Survivorship Study Groups. Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidance for the prevention of breast cancer-related arm lymphoedema (BCRAL): international Delphi consensus-based recommendations. *EClinicalMedicine*. 2024 Feb 2;68:102441. doi: 10.1016/j.eclinm.2024.102441. eCollection 2024 Feb. Impactfactor: 9,6

Wijlens KA, Witteveen A, Beenhakker L, Siemerink EJ, Achterkamp R, **Siesling S**, Vollenbroek-Hutten MM, Bode C. Face and content validity of a holistic assessment questionnaire to assess cancer-related fatigue after breast cancer. *Fatigue*. 2024 Aug 18;12(4):293-307. doi: 10.1080/21641846.2024.2389007. eCollection 2024. Impactfactor: 2,6

2.2 Proefschriften en promoties

Ankersmid JW. The use of outcome information in shared-decision-making about surveillance after breast cancer. Enschede: Universiteit Twente: 14 juni 2024. Promotor: **S Siesling**, S Drossaert.

Christenhusz A. Technical innovations in breast cancer surgery. Enschede: Universiteit Twente; 26 juni 2024. Promotor: B ten Haken. Graduation Committee: **S Siesling**, JT Tamsma, RM Verdaasdonk, JM Klaase, MD Dorrius.

Hendriks MP. Data-driven decision support for multidisciplinary clinical decision-making & reporting in breast cancer. Enschede: Universiteit Twente: 3 december 2024. Promotor: **S Siesling**, A Jager.

3 Bot-en wekedelentumoren

3.1 Publicaties met impactfactor

Bindels BJ, Mercier C, Gal R, Verlaan JJ, Verhoeff JJ, Dirix P, Ost P, Kasperts N, [van der Linden YM](#), Verkooijen HM, van der Velden JM. Stereotactic body and conventional radiotherapy for painful bone metastases: a systematic review and meta-analysis. JAMA Netw Open. 2024 Feb 5;7(2):e2355409. doi: 10.1001/jamanetworkopen.2023.55409. Impactfactor: 10,5

Debets P, Dreijerink KM, Engelsman AF, Dahele M, Haak HR, [Steenard RV](#), Kapiteijn E, Corssmit E, Menke-van der Houven van Oordt CW. Corrigendum to "Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: a population-based study" [Eur J Cancer 196 (2024) 113424]. Eur J Cancer. 2024 Nov 15;115123. doi: 10.1016/j.ejca.2024.115123. Online ahead of print. Impactfactor: 7,6

Debets P, Dreijerink KMA, Engelsman A, Dahele M, Haak HR, [Steenard RV](#), Kapiteijn E, Corssmit E, Menke-van der Houven van Oordt W. Response to Letter RE: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: a population-based study. Eur J Cancer. 2024 Mar 27;202:114035. doi: 10.1016/j.ejca.2024.114035. Online ahead of print. Impactfactor: 7,6

Roets E, Ijzerman NS, [Ho VK](#), Desar IM, Reyners AK, Gelderblom H, Grünhagen DJ, van Etten B, van Houdt WJ, van der Graaf WT, Steeghs N. Referral patterns of GIST patients: data from a nationwide study. Acta Oncol. 2024 Feb 14;63:28-34. doi: 10.2340/1651-226X.2024.23722. Impactfactor: 2,7

Schulpen M, Haveman LM, van der Heijden L, Kaal SE, Bramer JA, Fajardo RD, de Haan JJ, Hiemcke-Jiwa LS, ter Horst SA, Jutte PC, Schreuder HW, Tromp JM, van der Graaf WT, van de Sande MA, Gelderblom H, Merks JH, [Karim-Kos HE](#). The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlands did not change since the 1990s despite improved survival: a population-based study. Eur J Cancer. 2024 Jul 6;208:114209. doi: 10.1016/j.ejca.2024.114209. Online ahead of print. Impactfactor: 7,6

4 Darmkanker

4.1 Publicaties met impactfactor

Bonhof CS, de Rooij BH, Schoormans D, Wasowicz DK, Vreugdenhil G, **Mols F**. Sex differences in health-related quality of life and psychological distress among colorectal cancer patients: a 2-year longitudinal study. *J Cancer Surviv*. 2024 May 24. doi: 10.1007/s11764-024-01616-0. Online ahead of print.

Impactfactor: 3,1

Boute TC, Swartjes H, Greuter MJ, **Elferink MA**, van Eekelen R, **Vink GR**, de Wilt JH, Coupé VM. Cumulative incidence, risk factors and overall survival of disease recurrence after curative resection of stage II-III colorectal cancer: a population-based study. *Cancer Res Commun*. 2024 Feb 16. doi: 10.1158/2767-9764.CRC-23-0512. Online ahead of print.

Impactfactor: 2,0

de Back TR, Wu T, Schafrat PJ, ten Hoorn S, Tan M, He L, van Hooff SR, Koster J, Nijman LE, **Vink GR**, Beumer IJ, Elbers CC, Lenos KJ, Sommeijer DW, Wang X, Vermeulen L. A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues. *Life Sci Alliance*. 2024 May 23;7(8):e202402730. doi: 10.26508/lsa.202402730. Print 2024 Aug.

Impactfactor: 3,3

de Back TR, Wu T, Schafrat PJ, ten Hoorn S, Tan M, He L, van Hooff SR, Koster J, Nijman LE, **Vink GR**, Beumer IJ, Elbers CC, Lenos KJ, Sommeijer DW, Wang X, Vermeulen L. Correction: A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues. *Life Sci Alliance*. 2024 Jun 27;7(9):e202402889. doi: 10.26508/lsa.202402889. Print 2024 Sep.

Impactfactor: 3,3

de Back TR, Linszen JD, **van Erning FN**, Verbakel CS, Schafrat PJ, Vermeulen L, **de Hingh I**, Sommeijer DW. Incidence, clinical management and prognosis of patients with small intestinal adenocarcinomas from 1999 through 2019: a nationwide Dutch cohort study. *Eur J Cancer*. 2024 Jan 9;199:113529. doi: 10.1016/j.ejca.2024.113529. Online ahead of print.

Impactfactor: 7,6

de Vries-ten Have J, Manusama K, Verkaar AJ, **Beijer S**, Sommeijer DW, Kampman E, Winkens LH, Winkels RM. A randomized controlled intervention trial to study the effect of a personalized lifestyle program on cancer-related fatigue among colorectal cancer survivors: protocol for the SoFiT study. *Br J Nutr*. 2024 May 28;1-31. doi: 10.1017/S0007114524001107. Online ahead of print.

Impactfactor: 3,0

Derksen JW, Smit KC, Hoeven IW, **Sijtsma FP**, Koopman M, May AM. The nationwide Dietary Intake after Diagnosis and Colorectal Cancer Outcomes (PLCRC-PROTECT) cohort: study design, clinical characteristics and baseline health behaviors. *Cancer Epidemiol*. 2024 Dec 10;94:102724. doi: 10.1016/j.canep.2024.102724. Online ahead of print.

Impactfactor: 2,4

Franken IA, van der Baan FH, **Vink GR**, May AM, van Grevenstein WM, Koopman M, Roodhart JM. Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months. *Eur J Cancer*. 2024 Jul 10;208:114207. doi: 10.1016/j.ejca.2024.114207. Online ahead of print.

Impactfactor: 7,6

Galanos LJ, Rijken A, Elferink MA, Boerma D, Brandt-Kerkhof A, de Reuver PR, Tuynman JB, Kok NF, Hemmer PH, van Grevenstein WM, Huysentruyt C, **van Erning FN, de Hingh IH**. Differences in patient- and tumor characteristics, treatment and survival between patients with screen-detected versus clinically detected colorectal peritoneal metastases. *Eur J Surg Oncol*. 2024 Oct 25;51(1):108789. doi: 10.1016/j.ejso.2024.108789. Online ahead of print.

Impactfactor: 3,5

Kramer A, Greuter MJ, Schraa SJ, **Vink GR**, Phallen J, Velculescu VE, Meijer GA, van den Broek D, Koopman M, Roodhart JM, Fijneman RJ, Retèl VP, Coupé VM. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer. *Ther Adv Med Oncol*. 2024 Aug 21;16:17588359241266164. doi: 10.1177/17588359241266164. eCollection 2024. Impactfactor: 4,3

Mast IH, de Wilt JH, Duman B, Smit KC, Gootjes EC, **Vissers PA**, Rütten H, Nagtegaal ID, Hopman MT, May AM, Buffart LM. Physical activity at diagnosis is associated with tumor downstaging after neoadjuvant chemoradiotherapy in patients with rectal cancer. *Radiother Oncol*. 2024 Sep 10:110523. doi: 10.1016/j.radonc.2024.110523. Online ahead of print. Impactfactor: 4,9

Pennings AJ, **Vink GR**, van Kuijk S, Melenhorst J, Beets GL, May AM, Breukink SO. Quality of life and functional outcome of rectal cancer patients: a prospective cohort study. *Colorectal Dis*. 2024 Oct 2. doi: 10.1111/codi.17181. Online ahead of print. Impactfactor: 2,9

Pluimers JK, Wisse PH, van Leerdam ME, Dekker E, van Lansdorp-Vogelaar I, Tanis PJ, **Elferink MA**, den Hoed CM, Spaander MC. Risk of recurrence in screen-versus non screen-detected colorectal cancer patients. *Clin Gastroenterol Hepatol*. 2024 Sep 24:S1542-3565(24)00861-9. doi: 10.1016/j.cgh.2024.08.033. Online ahead of print. Impactfactor: 11,6

Polack M, Smit MA, van Pelt GW, Roodvoets AG, Meershoek-Klein Kranenbarg E, Putter H, Gelderblom H, Crobach AS, Terpstra V, Petrushevska G, Gašljević G, Kjær-Frifeldt S, de Cuba EM, Bulkman NW, **Vink GR**, Al Dieri R, Tollenaar RA, van Krieken JH, Mesker WE; UNITED Collaboration. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor-stroma ratio in colon cancer. *ESMO Open*. 2024 Apr 12;9(4):102988. doi: 10.1016/j.esmoop.2024.102988. Online ahead of print. Impactfactor: 7,1

Shen L, **van Gestel A, Prinsen P, Vink G, van Erning FN, Geleijnse G**, Kaptein M. Value of real-world evidence for treatment selection: a case study in colon cancer. *JCO Clin Cancer Inform*. 2024 May;8:e2300186. doi: 10.1200/CCI.23.00186. Impactfactor: 3,3

Swartjes H, **Sijsma FP, Elferink MA, van Erning FN**, Moons LM, Verheul HM, Berbée M, **Vissers PA**, de Wilt JH. Corrigendum to "Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021" Volume 205, July 2024, 114104. *Eur J Cancer*. 2024 Jun 11:114155. doi: 10.1016/j.ejca.2024.114155. Online ahead of print. Impactfactor: 7,6

Swartjes H, **Sijsma FP, Elferink MA, van Erning FN**, Moons LM, Verheul HM, Berbée M, **Vissers PA**, de Wilt JH. Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021. *Eur J Cancer*. 2024 May 7;205:114104. doi: 10.1016/j.ejca.2024.114104. Online ahead of print. Impactfactor: 7,6

Thomassen BJ, Kimman ML, Somers AM, Ponds RW, Dekker JW, van Leiden BL, **Vink GR**, de Groot JW, Melenhorst J, Reynders KM, Gielen CM, Weerts TH, Lutke Holzik MF, van Kuijk SM, Gidding-Slok AH, Breukink SO. Reply to: 'Enhancing patient-centered care and addressing psychosocial needs in colorectal cancer: the role of the ABCRC tool'. *Eur J Surg Oncol*. 2024 Jul 20:108552. doi: 10.1016/j.ejso.2024.108552. Online ahead of print. Impactfactor: 3,5

Thomassen BJ, Kimman ML, Somers AM, Ponds RW, Dekker JW, van Leiden BL, **Vink GR**, de Groot JW, Melenhorst J, Reynders KM, Gielen CM, Weerts TH, Lutke Holzik MF, van Kuijk SM, Breukink SO, Gidding-Slok AH. The assessment of burden of ColoRectal Cancer (ABCRC)-tool; a validity and reliability study. *Eur J Surg Oncol*. 2024 Feb 24;50(4):108032. doi: 10.1016/j.ejso.2024.108032. Online ahead of print. Impactfactor: 3,5

van de Vlasakker VC, Rauwerdink P, Rovers KP, Wassenaar EC, Creemers GJ, Los M, Burger JW, Nienhuijs SW, Kranenburg O, Wiezer MJ, Lurvink RJ, Boerma D, **de Hingh IH**. Patient-reported outcomes during first-line palliative systemic therapy alternated with pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: a single-arm phase II trial (CRC-PIPAC-II). *Surg Endosc*. 2024 Sep 16. doi: 10.1007/s00464-024-11185-z. Online ahead of print. Impactfactor: 2,4

van de Weerd S, Torang A, van den Berg I, Lammers V, van den Bergh S, Brouwer N, Nagtegaal ID, Koopman M, **Vink GR**, van der Baan FH, van Krieken H, Koster J, Ijzermans JN, Roodhart JM, Medema JP. Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer. *Int J Cancer*. 2024 Aug 8. doi: 10.1002/ijc.35120. Online ahead of print. Impactfactor: 5,7

van den Heuvel TB, Lurvink RJ, Rovers KP, van Hellemond IE, **de Hingh IH**. Systemic chemotherapy in addition to CRS-HIPEC for colorectal peritoneal metastases: a critical systematic review on the impact on overall survival. *J Surg Oncol*. 2024 Sep 11. doi: 10.1002/jso.27849. Online ahead of print. Impactfactor: 2,0

van der Kruijssen DE, Elias SG, van de Ven PM, van Rooijen KL, 't Lam-Boer J, **Mol L**, Punt CJ, Sommeijer DW, Tanis PJ, Nielsen JD, Yilmaz MK, van Riel JM, Wasowiz-Kemps DK, Loosveld OJL, van der Schelling GP, de Groot JW, van Westreenen HL, Jakobsen HL, Fromm AL, Hamberg P, Verseveld M, Jaensch C, Liposits GI, van Duijvendijk P, Hadj JO, van der Hoeven JA, Trajkovic M, de Wilt JH, Koopman M; CAIRO4 working Group (**de Hingh IH**) (see Appendix 1). Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group. *Ann Oncol*. 2024 Jun 7:S0923-7534(24)00722-1. doi: 10.1016/j.annonc.2024.06.001. Online ahead of print. Impactfactor: 56,7

van der Schee L, Haasnoot KJ, Elias SG, Gijsbers K, Alderlieste YA, Backes Y, van Berkel AM, Boersma F, ter Borg F, Breekveldt EC, Kessels K, Koopman M, Lansdorp-Vogelaar I, van Leerdam ME, Rasschaert G, Schreuder RM, Schrauwen RW, Seerden TC, Spanier MB, Terhaar Sive Droste JS, Toes-Zoutendijk E, Tuynman J, **Vink GR**, de Vos tot Nederveen Cappel WH, Vleggaar FP, Lacle MM, Moons LM. Oncological outcomes of screen-detected and non-screen-detected T1 colorectal cancers. *Endoscopy*. 2024 Feb 7. doi: 10.1055/a-2263-2841. Online ahead of print. Impactfactor: 11,5

van der Ven RG, van den Heuvel TB, Rovers KP, Nienhuijs SW, **van Erning FN, de Hingh IH**. ASO author reflections: Addressing hospital-based disparities in access to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) and survival in patients with isolated colorectal peritoneal metastases. *Ann Surg Oncol*. 2024 Mar 18. doi: 10.1245/s10434-024-15193-0. Online ahead of print. Impactfactor: 3,4

van der Ven RG, van den Heuvel TB, Rovers KP, Nienhuijs SW, Boerma D, van Grevenstein WM, Hemmer PH, Kok NF, Madsen EV, de Reuver P, Tuynman JB, van **Erning FN, de Hingh IH**. ASO visual abstract: Towards equal access to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and survival in patients with isolated colorectal peritoneal metastases: a nationwide population-based study. *Ann Surg Oncol*. 2024 Apr 24. doi: 10.1245/s10434-024-15261-5. Online ahead of print. Impactfactor: 3,4

van der Ven RG, van den Heuvel TB, Rovers KP, Nienhuijs SW, Boerma D, van Grevenstein WM, Hemmer PH, Kok NF, Madsen EV, de Reuver P, Tuynman JB, **van Erning FN, de Hingh IH**. Towards equal access to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and survival in patients with isolated colorectal peritoneal metastases: a nationwide population-based study. *Ann Surg Oncol*. 2024 Mar 7. doi: 10.1245/s10434-024-15131-0. Online ahead of print. Impactfactor: 3,4

van Erning FN, van den Heuvel TB, Sijtsma FP, Boerma D, Brandt-Kerkhof AR, Bremers AJ, van Duyn EB, van Grevenstein HM, Hemmer PH, Kok NF, Madsen E, de Reuver PR, Wiezer RJ, Witkamp AJ, Nienhuijs SW, Poelmann FB, Tuynman JB, Been LB, Rovers KP, **de Hingh IH**. An observational cohort of

patients with colorectal peritoneal metastases or pseudomyxoma peritonei treated with CRS-HIPEC: development and first results of the Dutch CRS-HIPEC quality registry. *Eur J Surg Oncol*. 2024 Aug 14;50(12):108568. doi: 10.1016/j.ejso.2024.108568. Online ahead of print. Impactfactor: 3,5

van Erven C, Cate DT, van Lieshout R, **Beijer S**, Dieleman J, Geertsema S, Jalink M, van der Meulen-Franken J, Rademakers N, Gillis C, Slooter G. Changes in nutritional status and effectiveness of the dietary intervention of multimodal prehabilitation for patients with colorectal cancer: a secondary analysis of the PREHAB randomized clinical trial. *Clin Nutr ESPEN*. 2024 Dec 27:S2405-4577(24)01569-9. doi: 10.1016/j.clnesp.2024.12.024. Online ahead of print. Impactfactor: 2,9

van Nassau SC, Bol GM, van der Baan FH, Roodhart JM, **Vink GR**, Punt CJ, May AM, Koopman M, Derksen JW. Harnessing the potential of real-world evidence in the treatment of colorectal cancer: where do we stand? *Curr Treat Options Oncol*. 2024 Feb 17. doi: 10.1007/s11864-024-01186-4. Online ahead of print. Impactfactor: 3,8

Verrijssen AE, **Evers J**, van der Sangen M, **Siesling S**, **Aarts MJ**, Struikmans H, Bloemers MC, Burger JW, **Lemmens V**, Braam PM, **Elferink MA**, Berbee M. Trends and variation in the use of radiotherapy in non-metastatic rectal cancer: a 14-year nationwide overview from the Netherlands. *Clin Oncol (R Coll Radiol)*. 2024 Jan 20:S0936-6555(24)00029-3. doi: 10.1016/j.clon.2024.01.013. Online ahead of print. Impactfactor: 3,2

Zwanenburg ES, El Klaver C, Wisselink DD, Punt CJ, Snaebjornsson P, Crezee J, Aalbers AG, Brandt-Kerkhof AR, Bremers AJ, Burger PJ, Fabry HF, Ferenschild FT, Festen S, van Grevenstein WM, Hemmer PH, de Hingh IH, Kok NF, Kusters M, Musters GD, Schoonderwoerd L, Tuijnman JB, van de Ven AW, van Westreenen HL, Wiezer MJ, Zimmerman DD, van Zweeken A, Dijkgraaf MG, Tanis PJ; COLOPEC Collaborators Group; COLOPEC Collaborators Group (**Mol L**). Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): 5-year results of a randomized multicenter trial. *J Clin Oncol*. 2024 Jan 10;42(2):140-145. doi: 10.1200/JCO.22.02644. Epub 2023 Nov 3. Impactfactor: 42,1

Zwart K, van Nassau SC, van der Baan FH, Koopman M, Snaebjornsson P, **van Gestel AJ**, **Vink GR**, Roodhart JM. Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab. *Br J Cancer*. 2024 May 20. doi: 10.1038/s41416-024-02711-w. Online ahead of print. Impactfactor: 6,4

4.2 Proefschriften en promoties

Rijken A. The burden of peritoneal metastases: exploring epidemiological and clinical aspects using population-based data. Maastricht: Maastricht University; 29 februari 2024. Promotoren: **IH de Hingh**. Copromotoren: **FN van Erning**.

Swartjes H. Colorectal cancer follow-up: peaks, patterns and personalisation. Nijmegen: Radboud Universiteit; 28 maart 2024. Promotoren: JH de Wilt, C Verhoef. Copromotor: **PA Vissers**.

5 Gynaecologische tumoren

5.1 Publicaties met impactfactor

Algera MD, van Driel WJ, Slangen BF, Wouters MW, Kruitwagen RF; participants of the Dutch Gynecological Oncology Audit Collaborator Group ([van der Aa MA](#)). Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: a population-based study from the Dutch Gynecological Oncology Audit. *Gynecol Oncol*. 2024 Apr 29;186:144-153. doi: 10.1016/j.ygyno.2024.04.002. Online ahead of print. Impactfactor: 4,5

Algera MD, van de Vijver KK, van Driel WJ, Slangen BF, Lof FC, [van der Aa MA](#), Kruitwagen RF, Lok CA. Outcomes of patients with early stage mucinous ovarian carcinoma: a Dutch population-based cohort study comparing expansile and infiltrative subtypes. *Int J Gynecol Cancer*. 2024 May 6;34(5):722-729. doi: 10.1136/ijgc-2023-004955. Impactfactor: 4,5

Dareng EO, Coetzee SG, Tyrer JP, Peng PC, Rosenow W, Chen S, Davis BD, Dezem FS, Seo JH, Nameki R, Reyes AL, [Aben KK](#), Anton-Culver H, Antonenkova NN, Aravantinos G, Bandera EV, Beane Freeman LE, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bolton KL, Brenton JD, Budzilowska A, Butzow R, Cai H, Campbell I, Cannioto R, Chang-Claude J, Chanock SJ, Chen K, Chenevix-Trench G; AOCs Group; Chiew YE, Cook LS, DeFazio A, Dennis J, Doherty JA, Dörk T, du Bois A, Dürst M, Eccles DM, Ene G, Fasching PA, Flanagan JM, Fortner RT, Fostira F, Gentry-Maharaj A, Giles GG, Goodman MT, Gronwald J, Haiman CA, Håkansson N, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Huang RY, Jensen A, Jones ME, Kang D, Karlan BY, Karnezis AN, Kelemen LE, Kennedy CJ, Khusnutdinova EK, Kiemenev LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Larson MC, Le ND, Lester J, Li L, Lubiński J, Lush M, Marks JR, Matsuo K, May T, McLaughlin JR, McNeish IA, Menon U, Missmer S, Modugno F, Moffitt M, Monteiro AN, Moysich KB, Narod SA, Nguyen-Dumont T, Odunsi K, Olsson H, Onland-Moret NC, Park SK, Pejovic T et al. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions. *AM J Hum Genet*. 2024 May 7:S0002-9297(24)00126-5. doi: 10.1016/j.ajhg.2024.04.011. Online ahead of print. Impactfactor: 8,1

[de Korte AM](#), [de Rooij BH](#), Boll D, van Loon I, Vincent N, Hoedjes M, [Lammens CR](#), [Mols F](#), van der Lee ML, Vos MC, [Ezendam NP](#). Barriers and facilitators for healthy lifestyle and recommendations for counseling in endometrial cancer follow-up care: a qualitative study. *J Psychosom Obstet Gynaecol*. 2024 Dec;45(1):2340465. doi: 10.1080/0167482X.2024.2340465. Epub 2024 Apr 15. Impactfactor: 2,1

[Ezendam NP](#), [de Rooij BH](#), Creutzberg CL, Kruitwagen RF, van Lonkhuijzen LR, Apperloo MJ, Gerestein K, Baalbergen A, Boll D, Vos MC, [van de Poll-Franse LV](#); ENSURE study group. Effect of reduced follow-up care on patient satisfaction with care among patients with endometrial cancer: the ENSURE randomized controlled trial. *Gynecol Oncol*. 2024 Jul 5;188:169-183. doi: 10.1016/j.ygyno.2024.06.020. Online ahead of print. Impactfactor: 4,5

Koek RC, [Wenzel H](#), Jonges GN, Lok CA, Zweemer R, Gerestein CG. Oncological outcomes after laparotomic, laparoscopic, and robot-assisted laparoscopic staging for early-stage high-intermediate or high-risk endometrial cancer. *Int J Gynecol Cancer*. 2024 Jul 23:ijgc-2024-005510. doi: 10.1136/ijgc-2024-005510. Online ahead of print. Impactfactor: 4,5

[Olthof EP](#), Bergink-Voorthuis BJ, [Wenzel HH](#), Mongula J, van der Velden J, Spijkerboer AM, Adam JA, Bekkers RL, Beltman JJ, Slangen BF, Nijman HW, Smolders RG, van Trommel NE, Zusterzeel PL, Zweemer RP, Stalpers LJ, Mom CH, [van der Aa MA](#). Diagnostic accuracy of MRI, CT, and [¹⁸F]FDG-PET-CT in detecting lymph node metastases in clinically early-stage cervical cancer - a nationwide Dutch cohort study. *Insights Imaging*. 2024 Feb 8;15(1):36. doi: 10.1186/s13244-023-01589-1. Impactfactor: 4,1

Olthof EP, Wenzel HH, van der Velden J, Stalpers LJ, Mom CH, **van der Aa MA**. Treatment strategies guided by [18F]FDG-PET/CT in patients with locally advanced cervical cancer and [18F]FDG-positive lymph nodes. *Cancers (Basel)*. 2024 Feb 8;16(4):717. doi: 10.3390/cancers16040717. Impactfactor: 4,5

Said SA, Int'Hout J, den Ouden JE, Walraven JE, **van der Aa MA**, de Hullu JA, van Altena AM. Development and internal validation of nomograms for survival of advanced epithelial ovarian cancer based on established prognostic factors and hematologic parameters. *J Clin Med*. 2024 May 9;13(10):2789. doi: 10.3390/jcm13102789. Impactfactor: 3,0

Servayge J, **Olthof EP**, Mom CH, **van der Aa MA**, **Wenzel HH**, van der Velden J, Nout RA, Boere IA, van Doorn HC, van Beekhuizen HJ. Survival of women with advanced stage cervical cancer: neo-adjuvant chemotherapy followed by radiotherapy and hyperthermia versus chemoradiotherapy. *Cancers (Basel)*. 2024 Feb 1;16(3):635. doi: 10.3390/cancers16030635. Impactfactor: 4,5

van der Eerden B, de Rooij BH, Schouten LJ, Boll D, van Hamont D, Vos MC, **Ezendam NP**. Quality of life among borderline ovarian tumor survivors: a comparison with survivors of early-stage ovarian cancer and a cancer-free population: a cross-sectional population-based PROFILES study. *Gynecol Oncol*. 2024 Aug 2;189:111-118. doi: 10.1016/j.ygyno.2024.07.681. Online ahead of print. Impactfactor: 4,5

van Wagenveld L, Colomban O, **van der Aa MA**, Freyer G, Sonke GS, Kruitwagen RF, You B. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". *J Gynecol Oncol*. 2024 Jan 8. doi: 10.3802/jgo.2024.35.e34. Online ahead of print. Impactfactor: 3,4

van Wagenveld L, van Nyen T, Annibali D, Sonke GS, Kruitwagen RF, Amant F, Horlings HM. High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer. *Oncologist*. 2024 Jun 26:oyae161. doi: 10.1093/oncolo/oyae161. Online ahead of print. Impactfactor: 4,8

Vos JA, Vos MC, van Lonkhuijzen LR, **van de Poll-Franse LV, Ezendam NP**. Less is more: the benefits of reduced follow-up in gynecologic cancers. *Gynecol Oncol*. 2024 Dec 13;192:178-180. doi: 10.1016/j.ygyno.2024.12.008. Online ahead of print. Impactfactor: 4,5

Voss FO, Fons G, Bruggink AH, **Wenzel HH**, Berkhof J, van Beurden M, Bleeker MC. Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: a population-based cohort study. *Gynecol Oncol*. 2024 Dec 12;192:163-170. doi: 10.1016/j.ygyno.2024.12.002. Online ahead of print. Impactfactor: 4,5

Wenzel HH, Schnack TH, **van der Aa MA**, Jensen PT, Høgdall CK, Hardie AN, Falconer H, Bekkers RL; Dutch, dANish and sweDish gynaEcoLoglcal ONcology (DANDELION) research group. Risk factors for lymph node metastasis in women with FIGO 2018 IA cervical cancer with a horizontal spread of > 7 mm. *Eur J Cancer*. 2024 Oct 5;212:115063. doi: 10.1016/j.ejca.2024.115063. Online ahead of print. Impactfactor: 7,6

Zelisse HS, van Gent MD, Mom CH, de Ridder S, Snijders ML, Heeling M, Stoter M, Broeks A, Horlings HM, Lok CA, Bosch SL, Piek JM, Bart J, Reyners AK, Wisman GB, Yigit R, Boere IA, Collée M, Groenendijk FH, Jansen MP, Roes EM, Hofhuis W, Hoogduin KJ, Alcalá LS, Smedts HP, Makkus AC, Nieuwenhuizen-de Boer GM, van Es N, Vencken PM, van Altena AM, Simons M, Hazelbag HM, Kagie MJ, Aliredjo R, Bonestroo TJ, Bosse T, de Kroon CD, Brinkhuis M, Janssen MJ, Koster NC, Kruse AJ, Gerstein CG, Jonges TG, Zweemer RP, Kooreman LF, Lambrechts S, Ebisch IM, de Kievit van der Heijden IM, Voorham QJ, **van der Aa MA**, Belien JA, van de Vijver MJ, Dijk F; Archipelago of Ovarian Cancer Research Consortium. Evaluation of the recently established Dutch nationwide Archipelago of Ovarian Cancer Research biobank. *Ann Diagn Pathol*. 2024 Nov 19;74:152411. doi: 10.1016/j.anndiagpath.2024.152411. Online ahead of print. Impactfactor: 1,5

5.2 Proefschriften en promoties

Olthof EP. Chasing nodes, saving lives?: lymph node metastases in cervical cancer. Amsterdam: Universiteit van Amsterdam; 27 september 2024. Promotor: LJ Stalpers. Copromotoren: **MA van der AA**, CH Mom.

6 Hemato-oncologie

6.1 Publicaties met impactfactor

Bennink C, **Brink M**, **Duijts SFA**, Scheurer H, Sonneveld P, Blommestein HM Changes in income and employment after diagnosis among patients with multiple myeloma in the Netherlands.. Clin Lymphoma Myeloma Leuk. 2024 Apr 19:S2152-2650(24)00152-6. doi: 10.1016/j.clml.2024.04.004. Online ahead of print.

Impactfactor: 2,7

Brink M, Huisman F, Meeuwes FO, van der Poel MW, Kersten MJ, Wondergem MJ, Bohmer LH, Woei-A-Jin FJ, Visser OJ, Oostvogels R, Jansen PM, Diepstra A, Sniijders TJ, Huls GA, Vermaat JS, Plattel WJ, Nijland M. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry. Blood Adv. 2024 May 13:bloodadvances.2023012531. doi: 10.1182/bloodadvances.2023012531. Online ahead of print.

Impactfactor: 7,4

Crespi CM, Sudan M, Juutilainen J, Roivainen P, Hareuveny R, Huss A, Kandel S, **Karim-Kos HE**, Thuróczy G, Jakab Z, Spycher BD, Flueckiger B, Vermeulen R, Vergara X, Kheifets L. International study of childhood leukemia in residences near electrical transformer rooms. Environ Res. 2024 May 15;249:118459. doi: 10.1016/j.envres.2024.118459. Epub 2024 Feb 11.

Impactfactor: 7,7

Darphin X, Moor J, da Silva CE, **Richters A**, Özdemir BC. Awareness of the impact of sex and gender in the disease risk and outcomes in hematology and medical oncology-a survey of Swiss clinicians. Cancer Rep (Hoboken). 2024 Jan 23:e1961. doi: 10.1002/cnr2.1961. Online ahead of print.

Impactfactor: 1,5

de Groot FA, Dekker TJ, Doorduyn JK, Böhringer S, **Brink M**, de Groen RA, de Haan LM, Woei-A-Jin FJ, Noordenbos T, Sijs-Szabo A, Oudshoorn MA, Lam KH, Diepstra A, te Boome LC, Terpstra V, Bohmer LH, Nicolae A, Posthuma EF, Koens L, Durian MF, Stavast J, van der Poel MW, Hamid MA, Stevens WB, van Rooij SL, Oostvogels RS, Mühlebner A, Neelis KJ, van den Brand M, Tousseyn T, Dierickx D, de Weerd O, Beeker A, Jansen PM, Kersten MJ, Zijlstra JM, Chamuleau ME, Veelken H, Bromberg JC, Nijland M, Vermaat JS. Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies. Eur J Cancer. 2024 Oct 13;213:115068. doi: 10.1016/j.ejca.2024.115068. Online ahead of print.

Impactfactor: 7,6

de Jonge AV, Bult JA, Karssing DF, Nijland M, Chamuleau ME, **Brink M**. A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma. Blood Cancer J. 2024 Jan 4;14(1):2. doi: 10.1038/s41408-023-00971-y.

Impactfactor: 12,9

Ekels A, **van de Poll-Franse LV**, Issa DE, Oosterveld M, van der Griend R, Hoogendoorn M, Koster A, Nijziel MR, Arts LP, Posthuma EF, **Oerlemans S**. Health care utilization up to 11 years after diagnosis among patients with a hematologic malignancy and its association with socioeconomic position. J Cancer Surviv. 2024 Sep 17. doi: 10.1007/s11764-024-01676-2. Online ahead of print.

Impactfactor: 3,1

Ekels A, **van de Poll-Franse LV**, Issa DE, Hoogendoorn M, Nijziel MR, Koster A, de Jong CN, Achouiti A, Thielen N, Tick LW, te Boome LCJ, Bohmer LH, Tiren-Verbeet NL, Veldhuis GJ, de Boer F, van der Klift M, Posthuma EF, **Oerlemans S**. Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry. Ann Hematol. 2024 Sep 16. doi: 10.1007/s00277-024-06006-1. Online ahead of print.

Impactfactor: 3,0

Hermans SJ, van der Maas NG, van Norden Y, **Dinmohamed AG**, **Berx E**, **Huijgens PC**, Rivera DR, de Claro RA, Pignatti F, Versluis J, Cornelissen JJ. Externally controlled studies using real-world data in patients with hematological cancers: a systematic review. JAMA Oncol. 2024 Aug 29. doi: 10.1001/jamaoncol.2024.3466. Online ahead of print.

Impactfactor: 22,3

Maas CC, van Klaveren D, **Durmaz M, Visser O**, Issa DE, Posthuma EF, Zijlstra JM, Chamuleau ME, Lugtenburg PJ, Kersten MJ, **Dinmohamed AG**. Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma. *Blood Cancer J*. 2024 Sep 12;14(1):157. doi: 10.1038/s41408-024-01137-0.

Impactfactor: 12,9

Oerlemans S, de Rooij BH, Bennink C, Bullinger L, Broijl A, d'Agostino M, Laane E, Lupo-Stanghellini MT, Perrot A, Wester R, Cursaru V, Scheurer H, Vesseur J, Dalal M, Sen R, Stamm T, Ludwig H, Sonneveld P. Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research. *Haematologica*. 2024 Feb 1. doi: 10.3324/haematol.2023.284282. Online ahead of print.

Impactfactor: 8,2

Pennings ER, **Durmaz M, Visser O**, Posthuma EF, Issa DE, Chamuleau ME, Lugtenburg PJ, Kersten MJ, **Dinmohamed AG**. Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands. *Blood Cancer J*. 2024 Jan 4;14(1):3. doi: 10.1038/s41408-023-00970-z.

Impactfactor: 12,9

Sant M, Vener C, Lillini R, Rossi S, Bonfarnuzzo S, Marcos-Gragera R, Maynadié M, Innos K, Paapsi K, **Visser O**, Bernasconi A, Demuru E, Di Benedetto C, Mousavi SM, Blum M, Went P, Serraino D, Bennett D, Sánchez MJ, De Angelis R; EURO CARE-6 Working Group. Long-term survival for lymphoid neoplasms and national health expenditure (EURO CARE-6): a retrospective, population-based study. *Lancet Oncol*. 2024 May 1:S1470-2045(24)00141-4. doi: 10.1016/S1470-2045(24)00141-4. Online ahead of print.

Impactfactor: 41,6

van Bergen MG, Kamphuis P, de Graaf AO, Salzbrunn JB, Koorenhof-Scheele TN, van Zeventer IA, **Dinmohamed AG**, Schuringa JJ, van der Reijden BA, Huls G, Jansen JH. Clonal hematopoiesis and myeloid skewing in older population-based individuals. *Am J Hematol*. 2024 Oct 21. doi: 10.1002/ajh.27495. Online ahead of print.

Impactfactor: 10,1

van der Straten L, Levin MD, **Dinnessen MA, Visser O**, Posthuma EFM, Doorduijn JK, Langerak AW, Kater AP, **Dinmohamed AG**. Causes of death among patients diagnosed with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1996-2020. *Hemasphere*. 2024 Nov 12;8(11):e70015. doi: 10.1002/hem3.70015. eCollection 2024 Nov.

Impactfactor: 11,9

van Lieshout R, Tick LW, Beckers EA, Biesbroek W, Dieleman JP, Dijkstra M, Groenesteijn W, Koene HR, Kranenburg S, van der Lee D, van der Put-van den Berg L, Rademakers N, Regelink JC, van Tilborg CJ, Westerweel PE, de Zeeuw S, Schouten HC, **Beijer S**. Changes in nutritional status and associations with physical and clinical outcomes in acute myeloid leukemia patients during intensive chemotherapy. *Eur J Clin Nutr*. 2024 Aug 10. doi: 10.1038/s41430-024-01488-8. Online ahead of print.

Impactfactor: 3,6

6.2 Overige publicaties

Meeuwes FO, **Brink M**, Plattel WJ, Vermaat JSP, Kersten MJ, Wondergem M, Visser O, van der Poel MWM, Oostvogels R, Woei-A-Jin FJSH, Böhmer L, Snijders TJF, Huls GA, Nijland M. Enteropathy-associated T-cell lymphoma: a population-based cohort study on incidence, treatment, and outcome in the Netherlands. *EJHaem*. 2024 Nov 29;5(6):1215-1222. doi: 10.1002/jha2.1049. eCollection 2024 Dec.

6.3 Proefschriften en promoties

van der Straten L. A lifelong journey: the epidemiology and molecular aspects of chronic lymphocytic leukemia. Rotterdam: Erasmus Universiteit; 11 september 2024. Promotoren: AW Langerak, AP Kater. Copromotoren: MD Levin, **AG Dinmohamed**.

7 Hoofdhalskanker

7.1 Publicaties met impactfactor

Frank MH, van Dijk BA, Schoonbeek RC, Zindler J, Devriese LA, van Es RJ, Merkx MA, de Bree R. Differences in the association of time to treatment initiation and survival according to various head and neck cancer sites in a nationwide cohort. *Radiother Oncol*. 2024 Jan 21;110107. doi: 10.1016/j.radonc.2024.110107. Online ahead of print. Impactfactor: 4,9

Jager EC, Metman MJ, Timmenga IA, Zandee WT, Jansen L, van Hemel BM, Lodewijk L, Vriens MR, van den Broek MF, Engelsman AF, Dreijerink KM, Netea-Maier RT, van Ginhoven TM, Peeters RP, de Heus E, Links TP, Kruijff S. Trends in the incidence, organization of care, and surgical treatment of medullary thyroid cancer: a population-based study. *Thyroid*. 2024 Dec 20. doi: 10.1089/thy.2024.0433. Online ahead of print. Impactfactor: 6,0

Padovan BV, Bijl MA, Langendijk JA, van der Laan HP, van Dijk BA, Festen S, Halmos GB. Evaluation of a new two-step frailty assessment of head and neck patients in a prospective cohort. *Eur Arch Otorhinolaryngol*. 2024 Apr 23. doi: 10.1007/s00405-024-08651-8. Online ahead of print. Impactfactor: 1,9

Scheurleer WF, van de Velde LJ, Devriese LA, de Ridder M, Louwman MWJ, Breimer GE, de Bree R, van Dijk BA, Rijken JA. Sinonasal mucosal melanoma in the Netherlands between 2001 and 2021: a clinical and epidemiological overview of 320 cases. *Eur Arch Otorhinolaryngol*. 2024 May 18. doi: 10.1007/s00405-024-08717-7. Online ahead of print. Impactfactor: 1,9

van de Velde LJ, Scheurleer WF, Braunius WW, Speksnijder CM, de Ridder M, devriese LA, de Bree R, Breimer GE, Rijken JA, van Dijk BA. Sinonasal squamous cell carcinoma in the Netherlands: a population-based study of 568 cases diagnosed in 2008-2021. *Head Neck*. 2024 Oct 16. doi: 10.1002/hed.27961. Online ahead of print. Impactfactor: 2,4

van de Velde LJ, Scheurleer WF, Braunius WW, Devriese LA, de Ridder M, de Bree R, Breimer GE, van Dijk BA, Rijken JA. Squamous cell carcinoma of the nasal vestibule in the Netherlands: a clinical and epidemiological review of 763 cases (2008-2021). *Head Neck*. 2024 Jul;46(7):1809-1821. doi: 10.1002/hed.27749. Epub 2024 Mar 21. Impactfactor: 2,4

van Velsen JS, van der Vegt B, Plaat BE, Langendijk JA, Epskamp-Kuijpers CC, van Dijk BA, Oosting SF. Nasopharyngeal carcinoma: nationwide trends in subtype-specific incidence and survival over 3 decades in a non-endemic area. *J Cancer Res Clin Oncol*. 2024 Jan 29;150(2):49. doi: 10.1007/s00432-023-05547-8. Impactfactor: 2,7

Virgili G, Capocaccia R, Botta L, Bennett D, Hadjistilianou T, Innos K, Karim-Kos H, Kuehni CE, Kuhnel U, Mazzini C, Canete Nieto A, Paapsi K, Parravano M, Ronckers CM, Rossi S, Stiller C, Vicini G, Visser O, Gatta G; EURO CARE-6 Working Group. Survival and health care burden of children with retinoblastoma in Europe. *JAMA Ophthalmol*. 2024 Oct 10. doi: 10.1001/jamaophthalmol.2024.4140. Online ahead of print. Impactfactor: 8,0

8 Huidkanker

8.1 Publicaties met impactfactor

Egeler MD, [van de Poll-Franse LV](#). Capturing the true effect of anti-PD-1 therapy on patients' health-related quality of life. *Lancet Oncol.* 2024 Dec;25(12):e617. doi: 10.1016/S1470-2045(24)00601-6. Impactfactor: 41,6

Fraterman I, Cerquin LE, de Ligt KM, van der Loo I, Wilgenhof S, [van de Poll-Franse LV](#), Beets-Tan RG, Tissier RL, Trebeschi S. Muscle atrophy and organ enlargement associated with quality of life during systemic therapy for melanoma: findings from an AI-based body composition analysis. *Eur Radiol.* 2024 Dec 19. doi: 10.1007/s00330-024-11289-z. Online ahead of print. Impactfactor: 4,7

van der Waa JD, van Midden D, Mellink JW, Flucke U, Bonenkamp JJ, Braam PM, [Drissen MM](#), [Louwman MW](#), Amir AL, Lubeek SF. The risk of subsequent skin cancer in patients with atypical fibroxanthoma or pleomorphic dermal sarcoma compared to the general population. *J Am Acad Dermatol.* 2024 Jun 4:S0190-9622(24)00844-2. doi: 10.1016/j.jaad.2024.05.075. Online ahead of print. Impactfactor: 12,8

9 Longkanker

9.1 Publicaties met impactfactor

Baum P, Cardoso R, Lenzi J, **Damhuis RA**, Verhagen AF, de Gendt C, Peacock H, de Leyn P, Christensen NL, Innos K, Oselin K, Zadnik V, Zagary T, Brenner H, Winter H. An international registry study of early-stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations. *Eur J Cancer*. 2024 Jul 19;209:114233. doi: 10.1016/j.ejca.2024.114233. Online ahead of print. Impactfactor: 7,6

Billings NE, **van den Hurk CJ**, Tromp V, **van de Poll-Franse LV**, Onwuteaka-Philipsen BD, Hugtenburg JG, Bogaard HJ, Belderbos J, Aaronson NK, Walraven I, Becker-Commissaris A; SYMPRO-Lung Consortium. Patient- vs physician-initiated response to symptom monitoring and health-related quality of life: the SYMPRO-Lung cluster randomized trial. *JAMA Netw Open*. 2024 Aug 1;7(8):e2428975. doi: 10.1001/jamanetworkopen.2024.28975. Impactfactor: 10,5

Damhuis R, Bahce I, Senan S. Association between PD-L1 score and the outcomes of consolidation durvalumab in a large nationwide series of patients with stage III NSCLC treated with chemoradiotherapy. *Clin Lung Cancer*. 2024 Jul 25:S1525-7304(24)00150-5. doi: 10.1016/j.clcc.2024.07.013. Online ahead of print. Impactfactor: 3,3

Damhuis RA, Dickhoff C, Bahce I, Senan S. Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017. *Lung Cancer*. 2024 Mar 7;190:107532. doi: 10.1016/j.lungcan.2024.107532. Online ahead of print. Impactfactor: 4,5

de Ruiter JC, van der Noort V, van Diessen JN, Smit EF, **Damhuis RM**, Hartemink KJ; ESLUNG group. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study. *Lung Cancer*. 2024 Apr 12;191:107792. doi: 10.1016/j.lungcan.2024.107792. Online ahead of print. Impactfactor: 4,5

Houda I, Dickhoff C, Uyl-de Groot CA, **Damhuis RA**, Reguart N, Provencio M, Levy A, Dziadziuszko R, Pompili C, Di Maio M, Thomas M, Brunelli A, Popat S, Senan S, Bahce I. Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective. *Lancet Reg Health Eur*. 2024 Mar 1;38:100841. doi: 10.1016/j.lanpe.2024.100841. eCollection 2024 Mar. Impactfactor: 13,6

Leunissen DJ, Moonen L, Thüsen JH, den Bakker MA, Hillen LM, van Weert TJ, Hausen AZ, van den Bosch TP, Lap LM, **Damhuis RA**, Reynaert NL, van den Broek EC; PALGA group; Fernandez-Cuesta L, Foll M, Alcalá N, Oates AS, Dingemans AC, Speel EJ, Derks JL. Identification of defined molecular subgroups based on immunohistochemical analyses and potential therapeutic vulnerabilities of pulmonary carcinoids. *J Thorac Oncol*. 2024 Nov 22:S1556-0864(24)02481-X. doi: 10.1016/j.jtho.2024.11.018. Online ahead of print. Impactfactor: 21,1

Moonen L, Derks JL, Hillen LM, van Suylen RJ, den Bakker MA, Thüsen JH, **Damhuis RA**, Buikhuisen WA, van den Broek EC, Maessen J, Maat AP, van Schil P, Speel EJ, Dingemans AC. Disease relapse in relation to lymph node sampling in lung carcinoid patients. *Endocr Relat Cancer*. 2024 Jul 8;31(9):e230202. doi: 10.1530/ERC-23-0202. Print 2024 Sep 1. Impactfactor: 4,1

Moonen L, Derks JL, den Bakker MA, Hillen LM, Jan van Suylen R, von der Thüsen JH, Lap LM, Marijnissen BJ, **Damhuis RA**, Smits KM, van den Broek EC, Buikhuisen WA; PALGA group; Dingemans AC, Speel EJ. OTP, CD44, and Ki-67: a prognostic marker panel for relapse free survival in patients with surgically resected pulmonary carcinoid. *Mod Pathol*. 2024 Dec 2:100677. doi: 10.1016/j.modpat.2024.100677. Online ahead of print.

Impactfactor: 7,1

Schouten RD, Schouten I, Schuurbijs MM, van der Noort V, **Damhuis RA**, van der Heijden EH, Burgers JA, Barlo NP, van Lindert AS, Maas KW, van den Brand JJ, Smit AA, van Haarst JM, van der Maat B, Schuuring E, Blaauwgeers H, Willems SM, Monkhorst K, van den Broek D, van den Heuvel MM.

[Optimising primary molecular profiling in non-small cell lung cancer](#). PLoS One. 2024 Jul 31;19(7):e0290939. doi: 10.1371/journal.pone.0290939. eCollection 2024.

Impactfactor: 2,9

Suazo-Zepeda E, Maas WJ, Vinke PC, Hiltermann TJ, **Aarts MJ**, de Bock GH, Heuvelmans MA. Trends in the prescription of immune checkpoint inhibitors for non-small cell lung cancer in the Netherlands from 2016 to 2020: a national cancer registry analysis. Transl Lung Cancer Res. 2024 Sep 30;13(9):2202-2211. doi: 10.21037/tlcr-24-264. Epub 2024 Sep 20.

Impactfactor: 4,0

van Doorn-Wink KC, Postmus PE, de Ruyscher D, **Damhuis RA**. Ninety-day mortality following curative intent radiotherapy for stage I-III lung cancer in the Netherlands. Radiother Oncol. 2024 Dec 6:110661. doi: 10.1016/j.radonc.2024.110661. Online ahead of print.

Impactfactor: 4,9

van Rossum PS, Wolfhagen N, **Damhuis RA**, Belderbos JS. An in-depth discussion on Dutch prediction models for relevant acute toxicity and 90-day mortality after stereotactic body radiotherapy for stage I NSCLC. J Thorac Oncol. 2024 Nov;19(11):e74-e77. doi: 10.1016/j.jtho.2024.09.1427.

Impactfactor: 21,1

van Rossum PS, Wolfhagen N, van Bockel LW, Coremans IE, van Es CA, van der Geest AM, De Jaeger KE, Wachters B, Knol HP, Koppe FL, Pomp J, Reymen BJ, Schinagl DA, Spoelstra FO, Tissing-Tan CJ, Peters M, van der Voort van Zijp NC, van der Wel AM, Wiegman EM, Wijsman R, **Damhuis RA**, Belderbos JS. Real-world acute toxicity and 90-day mortality in patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy. J Thorac Oncol. 2024 Jul 25:S1556-0864(24)00684-1. doi: 10.1016/j.jtho.2024.07.016. Online ahead of print.

Impactfactor: 21,1

9.2 Overige publicaties

Ruiter J, de Langen A, Monkhorst K, Veenhof A, Klomp H, Smit J, Smit E, **Damhuis R**, Hartemink K. Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancer. Acta Chir Belg. 2024 Feb 28:1-9. doi: 10.1080/00015458.2024.2322243. Online ahead of print.

10 Neuro-oncologie

10.1 Publicaties met impactfactor

Ho VK, Anten MM, **Garst A**, Bos EM, Snijders TJ, Eekers DB, Seute T; Dutch Brain Tumour Registry (DBTR) and the Dutch Society for Neuro-Oncology (LWNO). Initial management of newly diagnosed WHO grade 2-3 adult meningioma following surgery: results from the Dutch Brain Tumour Registry (2016-2021). J Neurooncol. 2024 Aug 29. doi: 10.1007/s11060-024-04730-2. Online ahead of print. Impactfactor: 3,2

Hoogendijk R, van der Lugt J, Kranendonk MEG, Gatta G, Capocaccia R, Hoving EW, Wesseling P, **Visser O**, van Vuurden DG, **Karim-Kos H**. Protocol for investigating data quality and reporting outcomes of pediatric gliomas in population-based cancer registry research. STAR Protoc. 2024 Feb 21;5(1):102905. doi: 10.1016/j.xpro.2024.102905. Online ahead of print. Impactfactor: 1,3

11 Upper GI & HPB

11.1 Publicaties met impactfactor

Caspers IA, Slagter AE, **Vissers PA**, Lopez-Yurda M, Beerepoot LV, Ruurda JP, Nieuwenhuijzen GA, Gisbertz SS, van Berge Henegouwen MI, Hartgrink HH, Goudkade D, Kodach LL, van Sandick JW, Verheij M, **Verhoeven RH**, Cats A, van Grieken NC. [Histopathological response to chemotherapy and survival of mucinous type gastric cancer](#). J Natl Cancer Inst. 2024 Sep 14:djae227. doi: 10.1093/jnci/djae227. Online ahead of print.

Impactfactor: 10,0

de Wilde AJ, de Jong EJ, Bruno MJ, Besselink MG, **van der Geest LG**, Geurts SM, Groot Koerkamp B, de Hingh IH, de Meijer VE, Miclea RL, Poley JW, Samarska IV, van Santvoort HC, Stommel MW, Voermans RP, Olde Damink SW, de Vos-Geelen J, Bouwense SA; Dutch Pancreatic Cancer Group. [Population-based cohort study on treatment and overall survival of patients clinically diagnosed with T1 ampullary cancer](#). Ann Surg. 2024 Oct 14. doi: 10.1097/SLA.0000000000006563. Online ahead of print.

Impactfactor: 7,9

Furumaya A, van Delden OM, de Wilde RF, de Vos-Geelen J, **van der Geest LG**; Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG) and the COVID & Cancer-NL consortium. [Impact of COVID-19 on incidence, treatment, and survival of patients with hepatocellular carcinoma in the Netherlands](#). Disaster Med Public Health Prep. 2024 Oct 30;18:e243. doi: 10.1017/dmp.2024.176.

Impactfactor: 1,9

Geerts JF, **Pape M**, **Vissers PA**, **Verhoeven RH**, Mostert B, Wijnhoven BP, Rosman C, van Hellemond IE, Nieuwenhuijzen GA, van Laarhoven HW. [Patient access to perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel in patients with resectable gastric cancer in the Netherlands](#). Eur J Cancer. 2024 Nov 20;214:115137. doi: 10.1016/j.ejca.2024.115137. Online ahead of print.

Impactfactor: 7,6

Geerts JF, van der Zijden CJ, van der Sluis PC, Spaander MC, Nieuwenhuijzen GA, Rosman C, van Laarhoven HW, **Verhoeven RH**, Wijnhoven BP, Lagarde SM, Mostert B. [Perioperative chemotherapy for gastro-esophageal or gastric cancer: anthracyclin triplets versus FLOT](#). Cancers (Basel). 2024 Mar 26;16(7):1291. doi: 10.3390/cancers16071291.

Impactfactor: 4,5

Gehrels AM, Wagner AD, Besselink MG, **Verhoeven RH**, van Eijck CH, van Laarhoven HW, Wilmink JW, **van der Geest LG**; Dutch Pancreatic Cancer Group. [Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study](#). Eur J Cancer. 2024 May 14;206:114117. doi: 10.1016/j.ejca.2024.114117. Online ahead of print.

Impactfactor: 7,6

Gertsen EC, van der Veen A, Brenkman HJ, Brosens LA, van der Post RS, **Verhoeven RH**, **Luijten JC**, **Vissers PA**, Vegt E, van Hillegersberg R, Siersema PD, Ruurda JP. [ASO Visual Abstract: Multimodal therapy versus primary surgery for gastric and gastroesophageal junction diffuse type carcinoma, with a focus on signet ring cell carcinoma: a nationwide study](#). Ann Surg Oncol. 2024 Jan 19. doi: 10.1245/s10434-023-14865-7. Online ahead of print.

Impactfactor: 3,4

Guchelaar NA, Noordman BJ, Welten MW, van Santen MT, de Neijs MJ, Koolen SL, **Verhoeven RH**, Oomen-de Hoop E, van der Sluis PC, Lagarde SM, van Laarhoven HW, de Hingh IH, Creemers GJ, Mostert B, Wijnhoven BP, Mathijssen RH. [Systemic treatment strategies and outcomes of patients with synchronous peritoneal metastases of gastric origin: a nationwide population-based study](#). J Natl Compr Canc Netw. 2024 Jul 29:1-8. doi: 10.6004/jnccn.2024.7013. Online ahead of print.

Impactfactor: 14,8

Kuijper SC, Gehrels AM, **van der Geest LG**, **Verhoeven RH**, Koerkamp BG, Molenaar IQ, Stommel MW, de Meijer VE, de Vos-Geelen J, Wumkes ML, Besselink MG, Wilmink JW, van Laarhoven HW; Dutch Pancreatic Cancer Group. [Survival scenarios of patients with localized and metastatic pancreatic](#)

adenocarcinoma: a population-based study. *Int J Cancer*. 2024 Nov 29. doi: 10.1002/ijc.35267. Online ahead of print.

Impactfactor: 5,7

Mackay TM, Latenstein AE, Augustinus S, **van der Geest LG**, Bogte A, Bonsing BA, Cirkel GA, Hol L, Busch OR, den Dulk M, van Driel LM, Festen S, de Groot DA, de Groot JB, Groot Koerkamp B, Haj Mohammad N, Haver JT, van der Harst E, de Hingh IH, Homs MY, Los M, Luelmo SA, de Meijer VE, Mekenkamp L, Molenaar IQ, Patijn GA, Quispel R, Römken TE, van Santvoort HC, Stommel MW, Venneman NG, Verdonk RC, van Vilsteren FG, de Vos-Geelen J, van Werkhoven CH, van Hooft JE, van Eijck CH, Wilmink JW, van Laarhoven HW, Besselink MG; Dutch Pancreatic Cancer Group.

Implementation of best practices in pancreatic cancer care in the Netherlands: a stepped-wedge randomized clinical trial. *JAMA Surg*. 2024 Feb 14. doi: 10.1001/jamasurg.2023.7872. Online ahead of print.

Impactfactor: 15,9

Mülder DT, van de Schootbrugge-vandermeer HJ, O'Mahony JF, Sun D, Han W, **Verhoeven RH**, van Loo M, van de Veerdonk W, Spaander MC, Lansdorp-Vogelaar I. Gastric cancer risk among immigrants and socioeconomic groups in the Netherlands. *Cancer Epidemiol Biomarkers Prev*. 2024 Nov 11. doi: 10.1158/1055-9965.EPI-24-0889. Online ahead of print.

Impactfactor: 3,7

van der Sluis K, Vollebergh MA, Kodach LL, van Dieren JM, **de Hingh IH**, Wijnhoven BP, **Verhoeven RH**, Sandick JW. The clinical implications of staging laparoscopy in the diagnostic workup of gastric cancer patients: a population based study. *Eur J Surg Oncol*. 2024 Aug 2;50(10):108569. doi: 10.1016/j.ejso.2024.108569. Online ahead of print.

Impactfactor: 3,5

van der Sluis K, Taylor SN, Kodach LL, van Dieren JM, de Hingh IH, Wijnhoven BP, **Verhoeven RH**, Vollebergh MA, van Sandick JW. Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: a nationwide study. *Eur J Cancer*. 2024 Jan 15;199:113541. doi: 10.1016/j.ejca.2024.113541. Online ahead of print.

Impactfactor: 7,6

van Velzen MJ, **Pape M**, Sprangers MA, van Kleef JJ, Mostert B, Beerepoot LV, Slingerland M, Gootjes EC, Hoekstra R, **van de Poll-Franse LV**, Haj Mohammad N, van Laarhoven HW. Chemotherapy-induced peripheral neuropathy in patients with gastroesophageal cancer. *J Natl Compr Canc Netw*. 2024 Jul 8:1-7. doi: 10.6004/jnccn.2024.7014. Online ahead of print.

Impactfactor: 14,8

Wang J, de Groot EM, Wu Z, **Verhoeven RH**, Haj Mohammad N, Mook S, Goense L, Markar SR, Ruurda JP, van Hillegersberg R. Evaluation of treatment strategies and survival of patients with cT4bM0 esophageal cancer: a nationwide cohort study. *Dig Surg*. 2024;41(4):171-180. doi: 10.1159/000540214. Epub 2024 Aug 17.

Impactfactor: 1,8

Wijma AG, Hogenbirk RN, Driessens H, Kluijfhooft DA, Jellema-Betten ES, Tjalsma-de Vries M, Liem MS, Nieuwenhuijs VB, Manusama EM, Hoogwater FJ, Nijkamp MW, **Beijer S**, Klaase JM. Nutritional support in pancreatic cancer patients and its effect on nutritional status: an observational regional HPB network study investigating current practice. *Support Care Cancer*. 2024 Jul 5;32(7):487. doi: 10.1007/s00520-024-08683-0.

Impactfactor: 2,8

12 Urogenitale kanker

12.1 Publicaties met impactfactor

Beeren I, Koops C, van der Heijden AG, **Aben KK**, Kiemeney LA, Witjes JA, Vrieling A. Lifestyle advice to patients with bladder cancer: a national survey of Dutch urologists. *Bladder Cancer*. 2024 Oct 23;10(3):215-220. doi: 10.3233/BLC-240048. eCollection 2024. Impactfactor: 1,0

Bosveld J, Nguyen TQ, Boormans JL, Witjes JA, van der Heijden AG, Mehra N, Kiemeney LA, **Aben KK**; ProBCI Study Group; Meijer RP, **Richters A**. The impact of positive surgical margins after cystectomy on oncological outcomes: a nationwide study. *BJU Int*. 2024 Dec 4. doi: 10.1111/bju.16611. Online ahead of print. Impactfactor: 3,7

Figaroa O, Zondervan P, Kessels R, Berkhof J, Aarts M, Hamberg P, Los M, Piersma D, Rikhof B, Suelmann B, Tascilar M, van der Veldt A, Verhagen P, Westgeest H, **Yildirim H**, Bex A, Bins A. PrimerX: a bayesian multistage cohort embedded randomised trial to evaluate the role of deferred local therapy of the primary tumour in combination with immune checkpoint inhibitor-based first-line therapy in metastatic renal cell carcinoma patients. *Eur Urol Open Sci*. 2024 Oct 14;70:28-35. doi: 10.1016/j.euros.2024.09.002. eCollection 2024 Dec. Impactfactor: 3,2

Heesterman BL, **Aben KK**, van den Bergh AC, van der Voort van Zyp JR, Bokhorst LP. Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: nationwide real-world data indicates a shift in men that benefit. *Urol Oncol*. 2024 May 8:S1078-1439(24)00433-2. doi: 10.1016/j.urolonc.2024.04.013. Online ahead of print. Impactfactor: 2,4

Jahreiß MC, Heemsbergen WD, **Aben KK**, Incrocci L. Risk factors for secondary bladder cancer following prostate cancer radiotherapy. *Transl Androl Urol*. 2024 Jul 31;13(7):1288-1296. doi: 10.21037/tau-23-667. Epub 2024 Jun 17. Impactfactor: 1,9

Jahreiß MC, Incrocci L, **Aben KK**, de Vries KC, Hoogeman M, Hooning MJ, Heemsberge WD. The impact of baseline health factors on second primary cancer risk after radiotherapy for prostate cancer. *Acta Oncol*. 2024 Jun 30;63:511-517. doi: 10.2340/1651-226X.2024.24334. Impactfactor: 2,7

Kiebach J, Beeren I, **Aben KK**, Witjes JA, van der Heijden AG, Kiemeney LA, Vrieling A. Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer. *Int J Cancer*. 2024 Nov 5. doi: 10.1002/ijc.35250. Online ahead of print. Impactfactor: 5,7

Nuijens ST, van Osch FH, **van Hoogstraten LM**, Witjes JA, **Aben KK**, Hermans TJ. Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes. *Urol Oncol*. 2024 Jan 17:S1078-1439(23)00511-2. doi: 10.1016/j.urolonc.2023.12.014. Online ahead of print. Impactfactor: 2,4

Pijpers OM, **van Hoogstraten LM**, Remmers S, Beijert IJ, Oddens JR, Alfred Witjes J, Kiemeney LA, **Aben KK**, Boormans JL. Risk of progression of high-grade primary T1 non-muscle-invasive bladder cancer: a contemporary cohort. *Eur Urol Oncol*. 2024 Sep 25:S2588-9311(24)00216-5. doi: 10.1016/j.euo.2024.09.006. Online ahead of print. Impactfactor: 8,3

Rajwa P, Borkowetz A, Abbott T, Alberti A, Bjartell A, Brash JT, Campi R, Chillelli A, Conover M, Constantinovici N, Davies E, De Meulder B, Eid S, Gacci M, Golozar A, Hafeez H, Haque S, Hijazy A, Hulsen T, Josefsson A, Khalid S, Kolde R, Kotik D, Kurki S, Lambrecht M, Leung CH, Moreno J, Nicoletti R, Nieboer D, Oja M, Palanisamy S, **Prinsen P**, Reich C, Raffaele Resta G, Ribal MJ, Gómez Rivas J,

Smith E, Snijder R, Steinbeisser C, Vandenberghe F, Cornford P, Evans-Axelsson S, N'Dow J, Willemse PM. Research protocol for an observational health data analysis on the adverse events of systemic treatment in patients with metastatic hormone-sensitive prostate cancer: big data analytics using the PIONEER platform. *Eur Urol Open Sci.* 2024 Mar 25;63:81-88. doi: 10.1016/j.euros.2024.02.019. eCollection 2024 May.
Impactfactor: 3,2

Remmers S, Beyer K, Lalmahomed TA, **Prinsen P**, **Horevoorts NJ**, Sibert NT, Kowalski C, Barletta F, Brunckhorst O, Gandaglia G, van der Voort van Zyp JRN, Smith EJ, Deschamps A, Collette L, Cornford P, Evans-Axelsson S, N'Dow J, Hemelrijck MV, Roobol MJ, Venderbos LDF; PIONEER Consortium. An overview of patient-reported outcomes for men with prostate cancer: results from the PIONEER Consortium. *Eur Urol Open Sci.* 2024 Dec 17;71:106-113. doi: 10.1016/j.euros.2024.11.009. eCollection 2025 Jan.
Impactfactor: 3,2

Richters A, Robbrecht DG, Meijer RP, van der Heijden AG, Kiemeney LA, van den Bosch J, Suelmann BB, Özdemir BC; ProBCI Study Group; Mehra N, **Aben KK**. Treatment patterns and use of immune checkpoint inhibitors among patients with metastatic bladder cancer in a Dutch nationwide cohort. *Eur Urol Open Sci.* 2023 Dec 20;59:50-54. doi: 10.1016/j.euros.2023.11.010. eCollection 2024 Jan.
Impactfactor: 3,2

Slotman E, **Richters A**, **Fransen HP**, Smilde TJ, van der Linden YM, **Siesling S**, **Aben KK**, **Raijmakers NJ**; ProBCI study group. Guidelines versus real-world data in metastatic bladder cancer: a population-based study on first-line chemotherapy treatment patterns. *Urol Oncol.* 2024 Nov 14:S1078-1439(24)00705-1. doi: 10.1016/j.urolonc.2024.10.026. Online ahead of print.
Impactfactor: 2,4

Tillier CN, Cox IL, Hagens MJ, Nicolai MP, van Muilekom HA, van Leeuwen PJ, **van de Poll-Franse LV**, van der Poel HG. Surgical and non-surgical predictors of long term erectile function after robot assisted radical prostatectomy. *Support Care Cancer.* 2024 Oct 21;32(11):738. doi: 10.1007/s00520-024-08936-y. eCollection 2024 Oct 21.
Impactfactor: 2,8

van der Meer DJ, **Karim-Kos HE**, Elzevier HW, Dinkelman-Smit M, Kerst JM, **Atema V**, Lehmann V, Husson O, van der Graaf WT. The increasing burden of testicular seminomas and non-seminomas in adolescents and young adults (AYAs): incidence, treatment, disease-specific survival and mortality trends in the Netherlands between 1989 and 2019. *ESMO Open.* 2024 Jan 19;9(2):102231. doi: 10.1016/j.esmoop.2023.102231. Online ahead of print.
Impactfactor: 7,1

van Doeveren T, Remmers S, **Atema V**, van den Bergh RC, Boevé ER, Cornel EB, van der Heijden AG, Hendricksen K, Cauberg EC, Jacobs RA, Kroon BK, Leliveld AM, Meijer RP, Merks B, Oddens JR, Roelofs L, Somford DM, de Vries P, Wijsman B, Windt WA, Zwaan PJ, van Leeuwen PJ, Boormans JL, **Aben KK**. Short-term changes in health-related quality of life of patients undergoing radical surgery for upper urinary tract urothelial carcinoma: results from a prospective phase 2 clinical trial. *Eur Urol Open Sci.* 2024 Jan 5;60:15-23. doi: 10.1016/j.euros.2023.12.005. eCollection 2024 Feb.
Impactfactor: 3,2

Vrieling A, Maurits JS, Gerritsen J, Buffart LM, **Aben KK**, Sedelaar JP, Bakker EA, Kiemeney LA. Associations of physical activity and sedentary time with health-related quality of life in patients with localized renal cell cancer: a cross-sectional analysis within the ReLife study. *Support Care Cancer.* 2024 Nov 18;32(12):800. doi: 10.1007/s00520-024-08969-3. eCollection 2024 Nov 18.
Impactfactor: 2,8

Yildirim H, Bins AD, **van den Hurk CJ**, van Moorselaar RJ, van Oijen MG, Bex A, Zondervan PJ, **Aben KK**. The impact of the COVID-19 pandemic on renal cancer care. *World J Urol.* 2024 Apr 13;42(1):231. doi: 10.1007/s00345-024-04925-2. eCollection 2024 Apr 13.
Impactfactor: 2,8

12.2 Overige publicaties

Osong B, Hasannejadasl H, van der Poel H, Vanneste B, van Roermund J, **Aben KK**, van Soest J, van Oort I, Hochstenbach L, **Bloemen-van Gurp EJ**, Dekker A, Fijten RR. The value of PROMs for predicting erectile dysfunction in prostate cancer patients with Bayesian network. Tech Innov Patient Support Radiat Oncol. 2024 Feb 13;31:100234. doi: 10.1016/j.tipsro.2024.100234. eCollection 2024 Sep.

12.3 Proefschriften en promoties

Houben LH. Exercise training in prostate cancer patients on androgen deprivation therapy. Maastricht: Maastricht University; 11 januari 2024. Promotor: LJ van Loon. Copromotoren: **S Beijer**, M Beelen.

B1 Impactfactoren tijdschriften

Tabel 1 Overzicht tijdschriften met impactfactor

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Acta Oncologica	2,7	2
AJH American Journal of Hematology	10,1	1
AJHG American Journal of Human Genetics	8,1	1
American Journal of Hospice and Palliative Medicine	1,5	1
Annals of Diagnostic Pathology	1,5	1
Annals of Hematology	3,0	1
Annals of Oncology	56,7	1
Annals of Surgery	7,9	1
Annals of Surgical oncology	3,4	6
Arthritis Care and Research	3,7	1
BJC British Journal of Cancer	6,4	3
BJN British Journal of Nutrition	3,0	1
BJS British Journal of Surgery	8,7	1
BJU international	3,7	1
Bladder Cancer	1,9	1
Blood Advances	7,4	1
Blood Cancer Journal	12,9	3
BMC Medical Research Methodology	3,9	1
BMC Medicine	7,1	1
BMC Palliative Care	2,5	1
BMJ Supportive and Palliative Care	2,0	1
Breast Cancer Research	6,1	1
Breast Cancer Research and Treatment	3,0	6
Cancer	6,1	1
Cancer Epidemiology	2,4	2
Cancer Epidemiology, Biomarkers & Prevention	3,7	1
Cancer Medicine	2,9	1
Cancer Reports	1,5	1
Cancer Research Communications	2,0	1
Cancers (Basel)	4,5	8
CGH Clinical Gastroenterology and Hepatology	11,6	1
Clinical and Translational Radiation Oncology	2,7	1
Clinical Lung Cancer	3,3	1
Clinical Lymphoma, Myeloma & Leukemia	2,7	1
Clinical Nutrition ESPEN	2,9	1
Clinical Oncology	3,2	3
Colorectal Disease	2,9	1
Critical Reviews in Oncology/Hematology	5,5	1
Current Breast Cancer Reports	1,0	1
Current treatment options in oncology	3,8	1
Death Studies	2,1	1
Digestive Surgery	1,8	1

Disaster Medicine and Public Health Preparedness	1,9	1
eClinicalMedicine	9,6	2
EJC European Journal of Cancer	7,6	16
EJSO European Journal of Surgical Oncology	3,5	9
Endocrine-Related Cancer	4,1	1
Endoscopy	11,5	1
Environmental Research	7,7	1
ESMO Open	7,1	7
European Archives of Oto-Rhino-Laryngology	1,9	2
European Journal of Cancer Care	1,8	1
European Journal of Clinical Nutrition	3,6	1
European Journal of Oncology Nursing	2,7	1
European Radiology	4,7	1
European Urology Oncology	8,3	1
European Urology Open Science	3,2	5
Fatigue: Biomedicine, Health & Behavior	2,6	1
Frontiers in Neuroinformatics	2,5	1
Frontiers in Oncology	3,5	2
Genetics in Medicine	6,7	1
Gynecologic Oncology	4,5	5
Haematologica	8,2	1
Head & Neck	2,4	2
Hemasphere	11,9	1
IJC International Journal of Cancer	5,7	7
IJIC International Journal of integrated care	2,6	1
Insights into Imaging	4,1	1
International Journal of Gynecological Cancer	4,5	2
JAAD Journal of the American Academy of Dermatology	12,8	1
JAMA Network Open	10,5	2
JAMA Oncology	22,3	2
JAMA Ophthalmology	8,0	1
JAMA Surgery	15,9	1
JCO Clinical Cancer Informatics	3,3	1
JCO Global Oncology	3,2	2
JCO Oncology Practice	4,7	2
JGO Journal of Gynecologic Oncology	3,4	1
JNCCN Journal of the Nat. Comp. Canc. Netw.	14,8	2
JNCI Cancer Spectrum	3,4	1
JNCI Journal of the National Cancer Institute	10,0	2
Journal of Cancer Research and Clinical Oncology	2,7	1
Journal of Cancer Survivorship	3,1	13
Journal of Clinical Epidemiology	7,3	1
Journal of Clinical Medicine	3,0	2
Journal of Clinical Oncology	42,1	1
Journal of Geriatric Oncology	3,0	1
Journal of Neuro-Oncology	3,2	1
Journal of Pain and Symptom Management	3,2	1
Journal of Palliative Care	1,3	1
Journal of Psychosomatic Obstetrics & Gynecology	2,1	1

Journal of Surgical Oncology	2,0	1
Journal of Thoracic Oncology	21,1	3
Life Science Alliance	3,3	2
Lung Cancer	4,5	2
Modern Pathology	7,1	1
Nature	50,5	1
npj Breast Cancer	6,6	1
OJRD Orphanet Journal of Rare Disease	3,4	2
Oncology	2,5	1
Palliative and Supportive Care	1,9	1
Palliative Medicine	3,6	1
Pharmacoepidemiology and Drug Safety	2,4	1
Plos One	2,9	2
Psychological Medicine	5,9	1
Psycho-Oncology	3,3	1
Quality of Life Research	3,3	3
Radiotherapy & Oncology	4,9	3
Royal Society Open Science	2,9	1
Scandinavian Journal of Medicine and Science in Sports	3,5	1
STAR Protocols	1,3	1
Supportive Care in Cancer	2,8	11
Surgical Endoscopy	2,4	1
TAU Translational Andrology and Urology	1,9	1
The Breast	5,7	3
The Lancet Oncology	41,6	2
The Lancet Regional Health Americas	7,0	1
The Lancet Regional Health Europe	13,6	1
The Oncologist	4,8	4
Therapeutic Advances in Medical Oncology	4,3	1
TLCR Translational Lung Cancer Research	4,0	1
Trials	2,0	1
Thyroid	6,0	1
Urologic Oncology: seminars	2,4	3
World Journal of Urology	2,8	1

Tabel 2 Overzicht tijdschriften zonder impactfactor

Acta Chirurgica Belgica	1
APJON Asia-Pacific Journal of Oncology Nursing	1
EJC: Paediatric Oncology	1
EJHaem	1
Huisarts en wetenschap	1
Studies in Health Technology and Informatics	4
Technical Innovations & Patient Support in Radiation Oncology	1

Integraal Kankercentrum
Nederland
info@iknl.nl
www.iknl.nl

